Selected Advocates
Abhishek Chakrala
Director, iCognitive Global
Abhishek Chakrala is the Chief Innovation Officer at iCognitive Global, a company dedicated to transforming the global rural economy by integrating emerging technologies and digitization with the traditional agriculture value chain. Abhishek also serves as an engineer at Tessonics and an advisor to AdvancingX and the Global Blockchain Foundation. Previously, Abhishek has served as the Executive Vice President for Grainster and the Chief Technology Officer for Stratodynamics. He has extensive technical experience working as an engineer at the ISRO Satellite Centre, Bharat Sanchar Nigam Limited, VVDN Technologies, and Riderless. In addition to winning the NASA Space Race Challenge, he was also named a semi-finalist in the Schneider Electric Go Green in the City Competition and won the special prize in the European Satellite Navigation Competition. He graduated with an MS in Electrical and Computer Engineering from the University of Windsor.
Abhishek Chakrala is the Chief Innovation Officer at iCognitive Global, a company dedicated to transforming the global rural economy by integrating emerging technologies and digitization with the traditional agriculture value chain. Abhishek also serves as an engineer at Tessonics and an advisor to AdvancingX and the Global Blockchain Foundation. Previously, Abhishek has served as the Executive Vice President for Grainster and the Chief Technology Officer for Stratodynamics. He has extensive technical experience working as an engineer at the ISRO Satellite Centre, Bharat Sanchar Nigam Limited, VVDN Technologies, and Riderless. In addition to winning the NASA Space Race Challenge, he was also named a semi-finalist in the Schneider Electric Go Green in the City Competition and won the special prize in the European Satellite Navigation Competition. He graduated with an MS in Electrical and Computer Engineering from the University of Windsor.
Alex Ratti
Founder/CEO, Light Switch Bio
Alex Ratti is the Founder and CEO of Light Switch Bio, a biotech company dedicated to redesigning and improving small molecule drugs for precision medicine. Alex graduated from Virginia Commonwealth University (VCU) with a BS and MS in Biomedical Engineering. During his graduate degree, Alex studied new treatment combinations for osteosarcoma at the Massey Cancer Center. Following his graduate degree, he transitioned to research for developing machine-learning software to auto-classify forensic samples in the Department of Forensic Science in collaboration with the VCU Venture Lab.
Alex Ratti is the Founder and CEO of Light Switch Bio, a biotech company dedicated to redesigning and improving small molecule drugs for precision medicine. Alex graduated from Virginia Commonwealth University (VCU) with a BS and MS in Biomedical Engineering. During his graduate degree, Alex studied new treatment combinations for osteosarcoma at the Massey Cancer Center. Following his graduate degree, he transitioned to research for developing machine-learning software to auto-classify forensic samples in the Department of Forensic Science in collaboration with the VCU Venture Lab.
Allen Waziri
CEO and Co-Founder, iCE Neurosystems
Dr. Allen Waziri is the co-founder and CEO of iCE Neurosystems Inc. and the director of the Brain Tumor Laboratory at Inova Neuroscience Institute. Prior to his time at iCE Neurosystems, Dr. Waziri served as a neurosurgeon at the Inova Neuroscience Institute and an assistant professor of neurosurgery at the University of Colorado Hospital. He received his Bachelor from Washington University in St. Louis, his medical degree from the University of Iowa and completed his residency at the Neurological Institute at Columbia University.
Dr. Allen Waziri is the co-founder and CEO of iCE Neurosystems Inc. and the director of the Brain Tumor Laboratory at Inova Neuroscience Institute. Prior to his time at iCE Neurosystems, Dr. Waziri served as a neurosurgeon at the Inova Neuroscience Institute and an assistant professor of neurosurgery at the University of Colorado Hospital. He received his Bachelor from Washington University in St. Louis, his medical degree from the University of Iowa and completed his residency at the Neurological Institute at Columbia University.
Amber Kaplan
Chief Scientific Officer, NKMax
Dr. Amber Kaplan is an immunologist with experience in innate immunology, infection, cancer, and autoimmunity. She brings a wealth of knowledge to NKMax providing critical input to the development and commercialization of our cellular immunotherapy products. Prior to joining NKMax, Dr. Kaplan worked in various areas of the biotechnology industry from start-up to venture capital. Dr. Kaplan earned her PhD in immunology from Cedars-Sinai Medical Center in Los Angeles, and she completed her post-doctoral work at UCLA in the Microbiology, Immunology, and Molecular Genetics department.
Dr. Amber Kaplan is an immunologist with experience in innate immunology, infection, cancer, and autoimmunity. She brings a wealth of knowledge to NKMax providing critical input to the development and commercialization of our cellular immunotherapy products. Prior to joining NKMax, Dr. Kaplan worked in various areas of the biotechnology industry from start-up to venture capital. Dr. Kaplan earned her PhD in immunology from Cedars-Sinai Medical Center in Los Angeles, and she completed her post-doctoral work at UCLA in the Microbiology, Immunology, and Molecular Genetics department.
Amir Bozorgzadeh
CEO, Virtuleap
Amir Bozorgzadeh is a market researcher, mobile games publisher, and tech writer who during the past 5 years has dove deep into all things emerging tech, and with a big crush for spatial computing: VR and AR.
You can find Amir's industry musings on VentureBeat.
Vancouver > Toronto > Dubai > Amsterdam > Lisbon.
Amir Bozorgzadeh is a market researcher, mobile games publisher, and tech writer who during the past 5 years has dove deep into all things emerging tech, and with a big crush for spatial computing: VR and AR.
You can find Amir's industry musings on VentureBeat.
Vancouver > Toronto > Dubai > Amsterdam > Lisbon.
Andrew Witzke
Senior Operating Associate, General Atlantic
Andrew Witzke is an Operating Senior Associate at General Atlantic, working within the General Atlantic Insights Group. In this role, he works to support investment teams and portfolio companies, providing strategic support and advice on topics such as top-line revenue growth, sales operations, and effectiveness, capability building and, change management.
Andrew is also a recognized expert in career coaching, having worked with 100+ job seekers, devoting 3,000+ hours to one-on-one interview coaching since 2013.
Prior to General Atlantic, Andrew was part of the McKinsey Restructuring and Transformation Services Academy, where he worked alongside senior client executives to deliver behavior change and capability-building programs that equipped organizations with capabilities to drive and sustain transformations.
Before McKinsey, Andrew worked on the Go-to-Market team at Cengage Learning, to revolutionize the higher education space, specifically with the sales and marketing departments, to offer a digital platform that makes the student learning experience more affordable and effective.
Prior to Cengage, Andrew was a senior business analyst with A.T. Kearney Management Consulting in Toronto, where he worked with numerous global companies operating in the consumer goods, financial services, and manufacturing sectors to set their overall strategic direction as well as create organizational structures and operating models that help to make these strategies a reality. His work covered many functional areas such as strategic planning, improving operations and change management.
Andrew is a graduate of the 2013 class from Queen's University with a dual degree from the Smith School of Business (Honours Bachelor of Commerce) and the Department of Political Studies (Bachelor of Arts).
Andrew Witzke is an Operating Senior Associate at General Atlantic, working within the General Atlantic Insights Group. In this role, he works to support investment teams and portfolio companies, providing strategic support and advice on topics such as top-line revenue growth, sales operations, and effectiveness, capability building and, change management.
Andrew is also a recognized expert in career coaching, having worked with 100+ job seekers, devoting 3,000+ hours to one-on-one interview coaching since 2013.
Prior to General Atlantic, Andrew was part of the McKinsey Restructuring and Transformation Services Academy, where he worked alongside senior client executives to deliver behavior change and capability-building programs that equipped organizations with capabilities to drive and sustain transformations.
Before McKinsey, Andrew worked on the Go-to-Market team at Cengage Learning, to revolutionize the higher education space, specifically with the sales and marketing departments, to offer a digital platform that makes the student learning experience more affordable and effective.
Prior to Cengage, Andrew was a senior business analyst with A.T. Kearney Management Consulting in Toronto, where he worked with numerous global companies operating in the consumer goods, financial services, and manufacturing sectors to set their overall strategic direction as well as create organizational structures and operating models that help to make these strategies a reality. His work covered many functional areas such as strategic planning, improving operations and change management.
Andrew is a graduate of the 2013 class from Queen's University with a dual degree from the Smith School of Business (Honours Bachelor of Commerce) and the Department of Political Studies (Bachelor of Arts).
Antonio Tito
Business Development, University of St. Thomas
Antonio Tito is enthusiastic about making a difference in the world through basic science research, innovation, and education. He is personally committed to paying close attention to detail in my research and daily activities. Antonio strives to challenge and motivate himself and his peers to innovate. He's a strong believer of creating a supportive but challenging environment in which we can feel encouraged to share novel approaches to the problems in hand.
Antonio Tito is enthusiastic about making a difference in the world through basic science research, innovation, and education. He is personally committed to paying close attention to detail in my research and daily activities. Antonio strives to challenge and motivate himself and his peers to innovate. He's a strong believer of creating a supportive but challenging environment in which we can feel encouraged to share novel approaches to the problems in hand.
Anuraag Gutgutia
Vice President, Portfolio Management, WorldQuant; 91springboard
Anuraag Gutgutia is Vice President, Portfolio Management at WorldQuant and member at the CEO Office looking after Strategic growth Initiatives. He is also an avid follower of the Start-up ecosystem, particularly interested in start-ups in the SaaS, FinTech, IoT and Healthcare domain.
Anuraag Gutgutia is Vice President, Portfolio Management at WorldQuant and member at the CEO Office looking after Strategic growth Initiatives. He is also an avid follower of the Start-up ecosystem, particularly interested in start-ups in the SaaS, FinTech, IoT and Healthcare domain.
Ashley Humphries
Fellow, Mount Sinai Innovation Partners
Ashley Humphries, PhD, is a biomedical scientist with an interest in supporting and advancing innovative research. Currently, she is a postdoctoral fellow at the Icahn School of Medicine at Mount Sinai, New York. She is also a fellow of Mount Sinai Innovation Partners, the commercialization arm of the Mount Sinai Health System, which facilitates real-world application of scientific discoveries and the advancement of science through research partnerships. Her scientific research focuses on how cell signaling links to cell behavior in both developmental and disease contexts. She completed her PhD in molecular and cellular biology at the London Research Institute, supported by Cancer Research UK.
Ashley Humphries, PhD, is a biomedical scientist with an interest in supporting and advancing innovative research. Currently, she is a postdoctoral fellow at the Icahn School of Medicine at Mount Sinai, New York. She is also a fellow of Mount Sinai Innovation Partners, the commercialization arm of the Mount Sinai Health System, which facilitates real-world application of scientific discoveries and the advancement of science through research partnerships. Her scientific research focuses on how cell signaling links to cell behavior in both developmental and disease contexts. She completed her PhD in molecular and cellular biology at the London Research Institute, supported by Cancer Research UK.
Avital Weiss
Regional Manager, ScienceAbroad
Dr. Avital Weiss is an experienced Project Manager with Global Leadership Experience. She brings 5 years of scientific leadership and project management experience with proven abilities to establish and execute global projects from basics by exploiting her skills to prioritize and promote projects to the next milestone while bridging mentalities, cultures, and capabilities to drive multidisciplinary teams to collaboration and success. Avital's communication skills have led her to articulate issues and navigate across teams to solve problems, therefore being able to influence and provide feedback to the leadership team with proactive solutions in mind. All is being performed while managing and implementing procedures that help the organization to maintain a well organized and smooth operation.
Avital is a Well Trained Scientist with Certified Business Acumen. Her passion has always been to understand the bigger picture and therefore she has always made sure to include relevant elements in her career by undertaking continuous professional learning and development. During her 10+ years of academic and professional experience, Avital gained in-depth scientific, clinical and business knowledge. She was gainfully employed in the agriculture, genomics and personalized medicine industries, where she was a key liaison to KOLs, an integral part in product development activities, and also an active participant in shaping and leading the company’s strategy.
Avital has a Positive and Energetic Approach to Work and Life. She gets motivated by solving difficult problems and driving projects to success. Avital brings strong leadership and interpersonal skills, analytical and problem-solving abilities and integrity to her work with a proactive mindset that bridges ideas to implementable solutions which can help move both internal and external stakeholders to quickly solve problems and continue growth.
Dr. Avital Weiss is an experienced Project Manager with Global Leadership Experience. She brings 5 years of scientific leadership and project management experience with proven abilities to establish and execute global projects from basics by exploiting her skills to prioritize and promote projects to the next milestone while bridging mentalities, cultures, and capabilities to drive multidisciplinary teams to collaboration and success. Avital's communication skills have led her to articulate issues and navigate across teams to solve problems, therefore being able to influence and provide feedback to the leadership team with proactive solutions in mind. All is being performed while managing and implementing procedures that help the organization to maintain a well organized and smooth operation.
Avital is a Well Trained Scientist with Certified Business Acumen. Her passion has always been to understand the bigger picture and therefore she has always made sure to include relevant elements in her career by undertaking continuous professional learning and development. During her 10+ years of academic and professional experience, Avital gained in-depth scientific, clinical and business knowledge. She was gainfully employed in the agriculture, genomics and personalized medicine industries, where she was a key liaison to KOLs, an integral part in product development activities, and also an active participant in shaping and leading the company’s strategy.
Avital has a Positive and Energetic Approach to Work and Life. She gets motivated by solving difficult problems and driving projects to success. Avital brings strong leadership and interpersonal skills, analytical and problem-solving abilities and integrity to her work with a proactive mindset that bridges ideas to implementable solutions which can help move both internal and external stakeholders to quickly solve problems and continue growth.
Aziz Alam
Director of Regulatory Affairs, Xeris Pharmaceuticals
Aziz Alam is an experienced pharmaceutical drug development professional with years of expertise in driving regulatory science for the development of new molecular entities in organizations ranging from small biotech to large multinational pharmaceutical conglomerate. He is responsible for providing strategic regulatory guidance and tactical oversight for drugs and biologics from discovery through phase 3 of clinical development. Additionally, he is directly responsible for leading all interactions and negotiations with the U.S. Food and Drug Administration (FDA), and other global health authorities.
Aziz Alam is an experienced pharmaceutical drug development professional with years of expertise in driving regulatory science for the development of new molecular entities in organizations ranging from small biotech to large multinational pharmaceutical conglomerate. He is responsible for providing strategic regulatory guidance and tactical oversight for drugs and biologics from discovery through phase 3 of clinical development. Additionally, he is directly responsible for leading all interactions and negotiations with the U.S. Food and Drug Administration (FDA), and other global health authorities.
Ben Laimon
Corporate Innovation, RTI International
Benjamin Laimon is the Senior Manager of Corporate Innovation at RTI International and co-founder of RTI HealthStory, a platform dedicated to helping patients navigate through complex health topics. At RTI International, he focuses on corporate engagement to integrate artificial intelligence and machine learning to multi-disciplinary research projects. He received his Master’s in Business Administration from the University of Maryland and BS from Michigan State University.
Benjamin Laimon is the Senior Manager of Corporate Innovation at RTI International and co-founder of RTI HealthStory, a platform dedicated to helping patients navigate through complex health topics. At RTI International, he focuses on corporate engagement to integrate artificial intelligence and machine learning to multi-disciplinary research projects. He received his Master’s in Business Administration from the University of Maryland and BS from Michigan State University.
Bill Draper
Founder & CTO, Gusto POS
Bill Draper is a builder of modern, innovative software products. Challenges the status quo. Over 20 years experience leading software development in a wide range of areas, from artificial intelligence to cloud architectures, advanced web architectures to industry-leading and award-winning point-of-sale for the hospitality industry. Designed and led the development of several of the largest restaurant POS systems worldwide.
Founded Gusto POS, architect of innovative enterprise POS product for large chains, raised seed and VC funding.
Software architect, designer and development manager for MICROS Simphony. Followed up with Simphony 2, rolled out at all Starbucks in the U.S. and Canada.
Prior to Simphony, Bill created the e7 product at MICROS.
Specialties: Cloud architectures, hybrid architectures, creating innovative vision, building talented teams, designing from first principles.
Bill Draper is a builder of modern, innovative software products. Challenges the status quo. Over 20 years experience leading software development in a wide range of areas, from artificial intelligence to cloud architectures, advanced web architectures to industry-leading and award-winning point-of-sale for the hospitality industry. Designed and led the development of several of the largest restaurant POS systems worldwide.
Founded Gusto POS, architect of innovative enterprise POS product for large chains, raised seed and VC funding.
Software architect, designer and development manager for MICROS Simphony. Followed up with Simphony 2, rolled out at all Starbucks in the U.S. and Canada.
Prior to Simphony, Bill created the e7 product at MICROS.
Specialties: Cloud architectures, hybrid architectures, creating innovative vision, building talented teams, designing from first principles.
Brad Fox
Founder, President, Fox Consulting Network
Brad Fox is an experienced and energetic entrepreneur, manager and leadership professional with proven technology commercialization and business development experience. Effective and encouraging consultant - assisting companies and organizations to set and reach business development objectives. Significant communication and management skills, enabling Brad to be an effective leader and team member of any organization.
Specialties: Experienced in Technology Commercialization and Regulatory management of medical devices as well as 3D printing and manufacturing processes:
• Management and Leadership Development
• Regulatory (FDA) and Quality (QSM)
• Contract development (licensing, etc.) and negotiation
• Patent development, evaluation and prosecution
• Technology Commercialization via TekniGROW
• Marketing Liaison; Research to Industry
• Grant Writing and Compliance Management
• 3D Printing / Additive Manufacturing
• Biomaterials, Microfluidics and 3D-MEMs
• Molecular and Proteomic Diagnostics
Brad Fox is an experienced and energetic entrepreneur, manager and leadership professional with proven technology commercialization and business development experience. Effective and encouraging consultant - assisting companies and organizations to set and reach business development objectives. Significant communication and management skills, enabling Brad to be an effective leader and team member of any organization.
Specialties: Experienced in Technology Commercialization and Regulatory management of medical devices as well as 3D printing and manufacturing processes:
• Management and Leadership Development
• Regulatory (FDA) and Quality (QSM)
• Contract development (licensing, etc.) and negotiation
• Patent development, evaluation and prosecution
• Technology Commercialization via TekniGROW
• Marketing Liaison; Research to Industry
• Grant Writing and Compliance Management
• 3D Printing / Additive Manufacturing
• Biomaterials, Microfluidics and 3D-MEMs
• Molecular and Proteomic Diagnostics
Brian Jahns
Senior Vice-President, Commercial and Business Development, Trillium Therapeutics
Dr. Brian E. Jahns is an accomplished business leader with robust and progressive experience in the biopharmaceutical industry.
Brian joined Trillium Therapeutics Inc in 2017 as Senior Vice-President, Commercial and Business Development. Trillium Therapeutics Inc is a clinical stage immune-oncology company developing innovative small molecules and biologic therapies for the treatment of cancer. In this role, Brian is responsible for providing commercial direction into the clinical and regulatory strategy, as well as executing business development activities.
Prior to working for Trillium Therapeutics, Brian worked at Hoffmann-La Roche Canada. Joining the organization in a medical capacity, Brian developed to succeed in various marketing and sales leadership roles where he was deeply involved in the successful launch and growth of several antiviral agents, transplant immunosuppressants and anticancer biologics. He grew a keen interest in all factors influencing optimized patient care, including the promise of personalized medicine, the intricacies of how medicines are used and the connection between funding and the ability to improve outcomes. Brian rose to become Vice President of Oncology Marketing and Sales, and then Vice President of Product Strategy at Roche Canada. There, he provided the strategic framework that allowed brands to exceed expectations, and he exemplified a key quality of a great leader – the ability to connect with others, and inspire them to greatness.
In an era that embraces innovation and patient centricity, Brian’s perspective is shaped by his experiences as a healthcare provider, researcher and marketer. Whether it is his ability to help others reach their professional potential or to help patients affected by rare diseases, Brian is a change agent who is not only in step with the growth of biopharmaceuticals - he is helping to drive it, to ensure that patients benefit.
Dr. Brian E. Jahns is an accomplished business leader with robust and progressive experience in the biopharmaceutical industry.
Brian joined Trillium Therapeutics Inc in 2017 as Senior Vice-President, Commercial and Business Development. Trillium Therapeutics Inc is a clinical stage immune-oncology company developing innovative small molecules and biologic therapies for the treatment of cancer. In this role, Brian is responsible for providing commercial direction into the clinical and regulatory strategy, as well as executing business development activities.
Prior to working for Trillium Therapeutics, Brian worked at Hoffmann-La Roche Canada. Joining the organization in a medical capacity, Brian developed to succeed in various marketing and sales leadership roles where he was deeply involved in the successful launch and growth of several antiviral agents, transplant immunosuppressants and anticancer biologics. He grew a keen interest in all factors influencing optimized patient care, including the promise of personalized medicine, the intricacies of how medicines are used and the connection between funding and the ability to improve outcomes. Brian rose to become Vice President of Oncology Marketing and Sales, and then Vice President of Product Strategy at Roche Canada. There, he provided the strategic framework that allowed brands to exceed expectations, and he exemplified a key quality of a great leader – the ability to connect with others, and inspire them to greatness.
In an era that embraces innovation and patient centricity, Brian’s perspective is shaped by his experiences as a healthcare provider, researcher and marketer. Whether it is his ability to help others reach their professional potential or to help patients affected by rare diseases, Brian is a change agent who is not only in step with the growth of biopharmaceuticals - he is helping to drive it, to ensure that patients benefit.
Brigitte Lavoie
CEO, Afin Limited
Dr. Brigitte Lavoie is a neuroscientist, an entrepreneur and an artist who loves to solve puzzles and find out how systems interact. She worked for over 20 years in sensori-motor interactions, giving her a keen interest in multidisciplinary teams. She combines her passion for science and technology and her desire to generate value from innovation to identify the best way to help innovators reach their goals. She has spent years developing and supporting collaboration between academia and industry in order to progress biomedical research along the translational pathway.
Dr. Brigitte Lavoie is a neuroscientist, an entrepreneur and an artist who loves to solve puzzles and find out how systems interact. She worked for over 20 years in sensori-motor interactions, giving her a keen interest in multidisciplinary teams. She combines her passion for science and technology and her desire to generate value from innovation to identify the best way to help innovators reach their goals. She has spent years developing and supporting collaboration between academia and industry in order to progress biomedical research along the translational pathway.
Cameron Weiner
Associate, BelHealth
Cameron Weiner is a Private Equity Associate at BelHealth Investment Partners, and leads business development for the firm. His responsibilities range from sourcing, deal origination and relationship management to structuring, due diligence and execution.
Cameron began his career in GE Capital's Leadership Development Program. The rotational program encompassed roles in credit underwriting, financial risk modeling, portfolio management, advisory controllership and commercial sales. Upon completing the leadership program, Cameron was as an Associate on GE’s Corporate M&A team, where he focused on GE's inorganic growth strategy (mergers, acquisitions, joint ventures, divestitures and equity investments) across all industries.
Cameron is a graduate (cum laude) of the University of North Carolina at Chapel Hill with a B.A. in Economics and a B.A. in Philosophy. As a Kenan-Flagler Business School student, he won the Kenneth Bartlett Howard BSBA Merit Scholarship to study abroad with the Chinese University of Hong Kong's international business program.
In his free time, Cameron loves basketball, chess and skiing.
Cameron Weiner is a Private Equity Associate at BelHealth Investment Partners, and leads business development for the firm. His responsibilities range from sourcing, deal origination and relationship management to structuring, due diligence and execution.
Cameron began his career in GE Capital's Leadership Development Program. The rotational program encompassed roles in credit underwriting, financial risk modeling, portfolio management, advisory controllership and commercial sales. Upon completing the leadership program, Cameron was as an Associate on GE’s Corporate M&A team, where he focused on GE's inorganic growth strategy (mergers, acquisitions, joint ventures, divestitures and equity investments) across all industries.
Cameron is a graduate (cum laude) of the University of North Carolina at Chapel Hill with a B.A. in Economics and a B.A. in Philosophy. As a Kenan-Flagler Business School student, he won the Kenneth Bartlett Howard BSBA Merit Scholarship to study abroad with the Chinese University of Hong Kong's international business program.
In his free time, Cameron loves basketball, chess and skiing.
Chandra Valmikinathan
Head of Strategy and Transformation, Ascensia Diabetes Care
Dr. Chandra Valmikinathan is a cross-functional leader with a proven track record in varied roles across the organization and functions, including:: Product development/R&D, management consulting, Corporate Strategy / Business development, GTM strategy and product launches.
Dr. Chandra Valmikinathan is a cross-functional leader with a proven track record in varied roles across the organization and functions, including:: Product development/R&D, management consulting, Corporate Strategy / Business development, GTM strategy and product launches.
Chris Haug
Chapter Director, Startup Grind; 360 Strategy Solutions Group, CEO
Everyone is passionate about something. Chris Haug's passion is to educate, inspire, and connect clients with the resources they need to grow phenomenally successful and profitable businesses.
Chris leads an extraordinary group of “on-demand” strategy, execution, and management specialists who create time, money, and resources for clients so they can focus on growing the business and not on back end, non-mission critical functions.
Chris challenges the "status-quo" and leads clients to be deliberately innovative, unique, and different. As a result, Chris's clients see what others don't, go where others won't, and find what other's can't. This enables them to grow 2.5x faster and become 3x more profitable, attract and retain great employees, raise more money, and develop impenetrable competitive advantages.
Chris solves complex business challenges by taking calculated risks using experience-backed judgement and a rare combination of creative and analytical decision-making skills. As a result, Chris created more than $200MM in corporate value by executing strategic roles that increased revenue by $80MM, reduced costs by $20MM, and improved working capital by $70MM, including $30MM in equity, debt, and alternative financing.
Chris's specialties include:
• Strategic planning, resource acquisition, execution, and "on demand" management services.
• Financing, capital raise, working capital optimization.
• Startup, operations, P/L & Balance Sheet leadership.
• FP&A, budgeting and forecasting accounting and audit management.
• Marketing, revenue development.
• HR, IT/IS, data analytics, technology commercialization.
• Risk mitigation, workouts, turnarounds, and distressed situation management.
Everyone is passionate about something. Chris Haug's passion is to educate, inspire, and connect clients with the resources they need to grow phenomenally successful and profitable businesses.
Chris leads an extraordinary group of “on-demand” strategy, execution, and management specialists who create time, money, and resources for clients so they can focus on growing the business and not on back end, non-mission critical functions.
Chris challenges the "status-quo" and leads clients to be deliberately innovative, unique, and different. As a result, Chris's clients see what others don't, go where others won't, and find what other's can't. This enables them to grow 2.5x faster and become 3x more profitable, attract and retain great employees, raise more money, and develop impenetrable competitive advantages.
Chris solves complex business challenges by taking calculated risks using experience-backed judgement and a rare combination of creative and analytical decision-making skills. As a result, Chris created more than $200MM in corporate value by executing strategic roles that increased revenue by $80MM, reduced costs by $20MM, and improved working capital by $70MM, including $30MM in equity, debt, and alternative financing.
Chris's specialties include:
• Strategic planning, resource acquisition, execution, and "on demand" management services.
• Financing, capital raise, working capital optimization.
• Startup, operations, P/L & Balance Sheet leadership.
• FP&A, budgeting and forecasting accounting and audit management.
• Marketing, revenue development.
• HR, IT/IS, data analytics, technology commercialization.
• Risk mitigation, workouts, turnarounds, and distressed situation management.
Chris Santa Maria
Consulting Manager, Alta Return
25+ years' experience in finance, accounting, IT, and marketing. 15+ years' experience with non-profits as board member. Chris Santa Maria's professional goal is to do her best and to inspire others to do the same.
Specialties: outsourced back office operations, SBIC, outsourced CCO, due diligence, valuations, investments, investor relations, mergers and acquisitions, fund accounting, partnership taxation, IT management, foreign tax compliance, non-profits, NAV system design and implementations, system integrations, venture capital, fund of funds, REIT's, start ups, private equity.
25+ years' experience in finance, accounting, IT, and marketing. 15+ years' experience with non-profits as board member. Chris Santa Maria's professional goal is to do her best and to inspire others to do the same.
Specialties: outsourced back office operations, SBIC, outsourced CCO, due diligence, valuations, investments, investor relations, mergers and acquisitions, fund accounting, partnership taxation, IT management, foreign tax compliance, non-profits, NAV system design and implementations, system integrations, venture capital, fund of funds, REIT's, start ups, private equity.
Christopher Kent
President & CEO, ODS Medical
Dr. Christopher Kent is the President and CEO of ODS Medical Inc, a medical device company focused on using Raman spectroscopy to detect tissue abnormalities in real-time. Prior to ODS Medical, Dr. Kent worked to push forward the pre-clinical development of a novel treatment target for glioblastoma at the Montreal Neurological Institute. Dr. Kent also has experience in business development and intellectual property at Bioastra Technologies, where he served as an Intellectual Property Strategy Consultant and the Director of Business Development. Dr. Kent received his BS in Developmental Biology from the University of Toronto and his PhD in Neuroscience from McGill University.
Dr. Christopher Kent is the President and CEO of ODS Medical Inc, a medical device company focused on using Raman spectroscopy to detect tissue abnormalities in real-time. Prior to ODS Medical, Dr. Kent worked to push forward the pre-clinical development of a novel treatment target for glioblastoma at the Montreal Neurological Institute. Dr. Kent also has experience in business development and intellectual property at Bioastra Technologies, where he served as an Intellectual Property Strategy Consultant and the Director of Business Development. Dr. Kent received his BS in Developmental Biology from the University of Toronto and his PhD in Neuroscience from McGill University.
Dariusz Wiśniewski
COO, Brainscan
Dariusz Wiśniewski is a communications specialist with years of experience in team management, sales and project management. Earlier, he was coordinator of Clipster preacceleration hub, which was awarded in the Polish final of the Central European Startup Awards competition, and a startup advisor in the pre-seed phase. Now Chief Operating Officer of Brainscan, Dariusz manages day to day operations, data aquisition and R&D support.
Dariusz Wiśniewski is a communications specialist with years of experience in team management, sales and project management. Earlier, he was coordinator of Clipster preacceleration hub, which was awarded in the Polish final of the Central European Startup Awards competition, and a startup advisor in the pre-seed phase. Now Chief Operating Officer of Brainscan, Dariusz manages day to day operations, data aquisition and R&D support.
David Vance
President, Vance Intellectual Property
• Over 20 years of patent experience in various fields, particularly the pharmaceutical and chemical arts
• Drafted and prosecuted numerous patent applications relating to chemical processes, pharmaceuticals (e.g., cardiovascular, inflammation, and obesity), semiconductor processing and substrates, organic light-emitting diodes, graphene production, and chemical sensors
• Have drafted, filed, and maintained an extensive docket of U.S. and foreign patent applications
• Enjoy providing technical counseling for in-licensing of technology, freedom-to-operate opinions, competitive analyses, and drug candidate protection
• Over 20 years of patent experience in various fields, particularly the pharmaceutical and chemical arts
• Drafted and prosecuted numerous patent applications relating to chemical processes, pharmaceuticals (e.g., cardiovascular, inflammation, and obesity), semiconductor processing and substrates, organic light-emitting diodes, graphene production, and chemical sensors
• Have drafted, filed, and maintained an extensive docket of U.S. and foreign patent applications
• Enjoy providing technical counseling for in-licensing of technology, freedom-to-operate opinions, competitive analyses, and drug candidate protection
Debjit Dutta
Senior Manager, National University of Singapore
Dr. Debjit Dutta is a forward thinking person who is passionate about innovation and commercialization of novel technologies in the therapeutics, diagnostics and medical device spectrum. He currently works as a Senior Manager at the Industry Liaison Office, NUS and has hands on experience in project management, innovation and operationalization of new initiatives.
Dr. Debjit Dutta is a forward thinking person who is passionate about innovation and commercialization of novel technologies in the therapeutics, diagnostics and medical device spectrum. He currently works as a Senior Manager at the Industry Liaison Office, NUS and has hands on experience in project management, innovation and operationalization of new initiatives.
Desiree Hollemon
Head of Clinical Affairs, Karius
Desiree Hollemon is the Head of Clinical Affairs at Karius, a biotech company dedicated to using microbial genomics to provide solutions for infectious disease. She has over twenty years of experience in global pharmaceutical and medical device development and commercialization. Prior to her role at Karius, Desiree served as the Senior Director of Clinical Development at Roche. She has also served in executive roles at several biotech companies including Galena Biopharma, Ariosa Diagnostics, ProteoGenix, and AVI Biopharma. She received her Bachelor’s in Nursing at the University of Texas Arlington, her Master’s in Public Health at Portland State University, and her Master’s of Science in Nursing at Oregon Health and Science University.
Desiree Hollemon is the Head of Clinical Affairs at Karius, a biotech company dedicated to using microbial genomics to provide solutions for infectious disease. She has over twenty years of experience in global pharmaceutical and medical device development and commercialization. Prior to her role at Karius, Desiree served as the Senior Director of Clinical Development at Roche. She has also served in executive roles at several biotech companies including Galena Biopharma, Ariosa Diagnostics, ProteoGenix, and AVI Biopharma. She received her Bachelor’s in Nursing at the University of Texas Arlington, her Master’s in Public Health at Portland State University, and her Master’s of Science in Nursing at Oregon Health and Science University.
Donatas Jonikas
CEO, Startup Marketing Supervisor, UAB "Marketologai"
Donatas Jonikas holds a PhD in Economics and a Master’s in Marketing Management with more than 12 years of experience in the field.
He has developed and helped to implement winning marketing strategies for more than 50 businesses in different industries around the globe.
He is the author of Startup Evolution Curve, one of top5 best-selling books on Amazon in startup and business innovation categories. In order to write it, he did a global research surveying 1,447 startup founders and running close to 500 in-depth interviews on how to successfully develop a startup business. His marketing manual for startups was featured on FORBES and highly evaluated by more than 30 international experts including CEOs of startup ecosystems, serial entrepreneurs, angel and VC investors.
Donatas Jonikas holds a PhD in Economics and a Master’s in Marketing Management with more than 12 years of experience in the field.
He has developed and helped to implement winning marketing strategies for more than 50 businesses in different industries around the globe.
He is the author of Startup Evolution Curve, one of top5 best-selling books on Amazon in startup and business innovation categories. In order to write it, he did a global research surveying 1,447 startup founders and running close to 500 in-depth interviews on how to successfully develop a startup business. His marketing manual for startups was featured on FORBES and highly evaluated by more than 30 international experts including CEOs of startup ecosystems, serial entrepreneurs, angel and VC investors.
Fahim Faruque
Postdoctoral Fellow, University of the Sciences
Fahim Faruque, PharmD is a pharmacist working in the pharmaceutical industry. He graduated from the University of Pittsburgh with a BS in molecular biology and completed his doctorate at the University of Maryland School of Pharmacy. He is an avid advocate of personalized medicine and has a deep interest in its intersection with real-world evidence and population health.
Fahim Faruque, PharmD is a pharmacist working in the pharmaceutical industry. He graduated from the University of Pittsburgh with a BS in molecular biology and completed his doctorate at the University of Maryland School of Pharmacy. He is an avid advocate of personalized medicine and has a deep interest in its intersection with real-world evidence and population health.
Faten Dhawi
Assistant Professor, King Faisal University
Dr. Faten Dhawi is an assistant professor and the Vice Dean of Development and Quality Assurance at King Faisal University. She has over a decade of experience in biochemistry and agricultural science and has contributed to 20 peer reviewed publications. Dr. Dhawi received her PhD in Biochemistry and Molecular Biology from Michigan Technological University.
Dr. Faten Dhawi is an assistant professor and the Vice Dean of Development and Quality Assurance at King Faisal University. She has over a decade of experience in biochemistry and agricultural science and has contributed to 20 peer reviewed publications. Dr. Dhawi received her PhD in Biochemistry and Molecular Biology from Michigan Technological University.
Frank Kuchinski
Founder, Mentorset
Frank Kuchinski is a polymath and systems thinker who always brings a fresh perspective to startups and new initiatives at large organizations. From implementing large enterprise platforms such as ServiceNow and Adobe Experience Manager (AEM) to working with startups designing cloud based IoT solutions, Frank's approach is to use the best parts of lean startup, design thinking, and Kaizen to make initiatives successful.
Frank is pre-disposed to taking action and bringing people together to make program management work and projects successful. He likes big challenges and is not afraid to fail or to try something no one else has. Frank is equally comfortable spending the day with a CEO or software developer.
Frank goes beyond strong technology skills and has subject matter expertise in: internet of things, healthcare, finance, cleantech, continuous personal improvement, leadership, customer engagement, behavioral science, positive psychology, and developing an entrepreneurial mindset having collaborated with many thought leaders in these spaces.
Hands-on skills include: AWS, Adobe Experience Manager, ServiceNow, Service Management, ITIL, Business Analysis, Needs Analysis, Project Management, Product / Market Fit, Use Cases, Responsive Design, Mobile / iPad UX Design, Quality Assurance, CRM, Workflow, Six Sigma, and Change Management.
Frank Kuchinski is a polymath and systems thinker who always brings a fresh perspective to startups and new initiatives at large organizations. From implementing large enterprise platforms such as ServiceNow and Adobe Experience Manager (AEM) to working with startups designing cloud based IoT solutions, Frank's approach is to use the best parts of lean startup, design thinking, and Kaizen to make initiatives successful.
Frank is pre-disposed to taking action and bringing people together to make program management work and projects successful. He likes big challenges and is not afraid to fail or to try something no one else has. Frank is equally comfortable spending the day with a CEO or software developer.
Frank goes beyond strong technology skills and has subject matter expertise in: internet of things, healthcare, finance, cleantech, continuous personal improvement, leadership, customer engagement, behavioral science, positive psychology, and developing an entrepreneurial mindset having collaborated with many thought leaders in these spaces.
Hands-on skills include: AWS, Adobe Experience Manager, ServiceNow, Service Management, ITIL, Business Analysis, Needs Analysis, Project Management, Product / Market Fit, Use Cases, Responsive Design, Mobile / iPad UX Design, Quality Assurance, CRM, Workflow, Six Sigma, and Change Management.
James Leveille
President & CIO, Embarc.biz
James Leveille enjoyed a successful decade long career in information and communications systems management before embarking on his entrepreneurial journey to chatter the barriers to business success for those less privileged. Haitian born, he attended the State University of New York at Stony Brook, where he studied mathematics but also indulged in the unique undergraduate research program of this top five public research institution. With the guidance of top researchers and the pioneers of the early Internet, he acquired the systems admin and programming skills to land a top paying job at the Memorial Sloan Kettering Cancer Center in NYC. His career quickly blossomed thereafter in progressively more challenging roles at companies such as Kentetsu World Express, Olympus America, Dime Savings Bank, Verizon, North American Telecom and Adecco.
Having failed to actually capitalize on the first Internet bubble, Mr. Leveille has spent the last 12 years assisting minority and women entrepreneurs to adopt and develop new technologies ahead of the next economic expansion. To accomplish this, he designed a business incubator model called Emerging and Minority Business Advanced Resource Center or EMBARC to launch new ventures and innovations from a facility while operating virtually as an incubator without walls. In turn, the EMBARC.biz Web portal is being developed as an intelligent business development platform to enable digital entrepreneurs of the 21st Century knowledge economy. Leveraging regulated crowdfunding, crowdsourcing, open innovation, and strategic corporate and university partnerships, EMBARC.biz will bring unique assets and capacity to women and minority-owned startups and small businesses to give them the competitive edge in the technology-driven global marketplace.
James Leveille enjoyed a successful decade long career in information and communications systems management before embarking on his entrepreneurial journey to chatter the barriers to business success for those less privileged. Haitian born, he attended the State University of New York at Stony Brook, where he studied mathematics but also indulged in the unique undergraduate research program of this top five public research institution. With the guidance of top researchers and the pioneers of the early Internet, he acquired the systems admin and programming skills to land a top paying job at the Memorial Sloan Kettering Cancer Center in NYC. His career quickly blossomed thereafter in progressively more challenging roles at companies such as Kentetsu World Express, Olympus America, Dime Savings Bank, Verizon, North American Telecom and Adecco.
Having failed to actually capitalize on the first Internet bubble, Mr. Leveille has spent the last 12 years assisting minority and women entrepreneurs to adopt and develop new technologies ahead of the next economic expansion. To accomplish this, he designed a business incubator model called Emerging and Minority Business Advanced Resource Center or EMBARC to launch new ventures and innovations from a facility while operating virtually as an incubator without walls. In turn, the EMBARC.biz Web portal is being developed as an intelligent business development platform to enable digital entrepreneurs of the 21st Century knowledge economy. Leveraging regulated crowdfunding, crowdsourcing, open innovation, and strategic corporate and university partnerships, EMBARC.biz will bring unique assets and capacity to women and minority-owned startups and small businesses to give them the competitive edge in the technology-driven global marketplace.
James Seeto
President, JC2 Consulting
James Seeto is an experienced executive search professional with a record of accomplishment in retained executive search and corporate in-house executive search. His focus has been on recruiting for VP, Director and key niche positions in all functions from Senior Executives, Operations, R&D, Finance, Marketing and Sales.
Additionally, James provides corporate leadership, sales and creativity training internationally and has authored the best selling book, "The 5 Keys to Hypnotic Selling".
Specialties: Wireless, Life Sciences, Telecommunications, Specialty Chemicals, Medical Device, Food Ingredients, Manufacturing, Marketing, Sales, Finance, Career and Life Coaching, Influence and Persuasion training and organizational consulting.
James Seeto is an experienced executive search professional with a record of accomplishment in retained executive search and corporate in-house executive search. His focus has been on recruiting for VP, Director and key niche positions in all functions from Senior Executives, Operations, R&D, Finance, Marketing and Sales.
Additionally, James provides corporate leadership, sales and creativity training internationally and has authored the best selling book, "The 5 Keys to Hypnotic Selling".
Specialties: Wireless, Life Sciences, Telecommunications, Specialty Chemicals, Medical Device, Food Ingredients, Manufacturing, Marketing, Sales, Finance, Career and Life Coaching, Influence and Persuasion training and organizational consulting.
Jamie Van Iderstine
Vice President Client Engagement, Cyan Health
Jamie Van Iderstine, Vice President of Client Engagement, sits on the leadership team of Cyan Health, where she develops comprehensive and high-impact market access strategies for a spectrum of biopharma clients, large and small, across many categories, including multiple rare diseases. Prior to her tenure at Cyan, Jamie cultivated her deep market access expertise at Ogilvy Commonhealth, where she led market access launches in complex disease states, including pulmonary hypertension and cystic fibrosis. With experience navigating all points in the product life cycle and addressing a wide range of market scenarios, Jamie specializes in connecting the dots of opportunity required to maximize access potential for pharmaceutical brands. Challenged daily to overcome the obstacles that stand between patients and the therapies they need, Jamie has developed a passion for principles of patient access and affordability.
Jamie Van Iderstine, Vice President of Client Engagement, sits on the leadership team of Cyan Health, where she develops comprehensive and high-impact market access strategies for a spectrum of biopharma clients, large and small, across many categories, including multiple rare diseases. Prior to her tenure at Cyan, Jamie cultivated her deep market access expertise at Ogilvy Commonhealth, where she led market access launches in complex disease states, including pulmonary hypertension and cystic fibrosis. With experience navigating all points in the product life cycle and addressing a wide range of market scenarios, Jamie specializes in connecting the dots of opportunity required to maximize access potential for pharmaceutical brands. Challenged daily to overcome the obstacles that stand between patients and the therapies they need, Jamie has developed a passion for principles of patient access and affordability.
Jeff Lee
President | eCOA & Patient Engagement, Bracket
Jeff Lee is founder and CEO of mProve Health, a leading provider of mobile technologies that connect and engage patients with global clinical research studies. mProve Health, headquartered in Washington, DC, is Jeff’s fourth entrepreneurial technology venture. His prior ventures pioneered the mobile engagement work for the American Idol text-to-vote campaign, Barack Obama’s 2008 campaign, and other high profile projects for Fortune 500 companies including Disney, MasterCard, and Exxon Mobil. He started his career as a corporate strategy consultant at Ernst & Young. Since founding mProve Health in 2010, Jeff has grown the company globally. Today, mProve’s applications are used by 18 of the top 20 pharmaceutical companies, 15,000 clinical research sites in over 60 countries, and they are translated in over 50 languages.
Jeff Lee is founder and CEO of mProve Health, a leading provider of mobile technologies that connect and engage patients with global clinical research studies. mProve Health, headquartered in Washington, DC, is Jeff’s fourth entrepreneurial technology venture. His prior ventures pioneered the mobile engagement work for the American Idol text-to-vote campaign, Barack Obama’s 2008 campaign, and other high profile projects for Fortune 500 companies including Disney, MasterCard, and Exxon Mobil. He started his career as a corporate strategy consultant at Ernst & Young. Since founding mProve Health in 2010, Jeff has grown the company globally. Today, mProve’s applications are used by 18 of the top 20 pharmaceutical companies, 15,000 clinical research sites in over 60 countries, and they are translated in over 50 languages.
John Mayfield
Director, Corporate and Business Development, Voyager Therapeutics
John Mayfield is a Director of Corporate and Business Development at Voyager Therapeutics, a company developing life-changing gene therapies from discovery, preclinical and clinical development, through to commercialization. Dr. Mayfield was previously an Associate Director of Corporate and Business Development at Foundation Medicine, a company specialized in genomic testing for cancer patients. Before this time he held roles as a scientist at Foundation Medicine and in the clinical laboratory at Illumina, along with postdoctoral research positions at Duke University Institute of Genome Sciences and Policy and Washington University School of Medicine. Dr. Mayfield earned his Ph.D. in Cellular/Molecular Biology from the University of Florida.
John Mayfield is a Director of Corporate and Business Development at Voyager Therapeutics, a company developing life-changing gene therapies from discovery, preclinical and clinical development, through to commercialization. Dr. Mayfield was previously an Associate Director of Corporate and Business Development at Foundation Medicine, a company specialized in genomic testing for cancer patients. Before this time he held roles as a scientist at Foundation Medicine and in the clinical laboratory at Illumina, along with postdoctoral research positions at Duke University Institute of Genome Sciences and Policy and Washington University School of Medicine. Dr. Mayfield earned his Ph.D. in Cellular/Molecular Biology from the University of Florida.
Jonas Moses
Director of Research, Clinical Director; EnVision Eye Center, Total Science Inc.
Jonas Moses, PhD PA, is the Director of Research and Clinical Director for the Mexico-based EnVision Eye Institute (www.ojos1.com). He also is a co-founder, former medical information officer and technical advisor to CYSEC LLC (www.cyberscureid.com), a Healthcare IT middleware cybersecurity company. Dr. Moses is a biomedical, scientific, and technical serial innovator. He has been awarded three US patents and has another dozen or more patents-pending. Moses’ career emphasis has been translational research, with professional experiences spanning academic, government and industrial laboratory research, technology transfer, scientific and technical liaising and commercialization of innovation. He has consulted with other scientists, governmental leaders, policy-makers, industry professionals and academes throughout the US, as well as in Europe, Asia and Latin America. He earned his undergraduate degree in Biology, from the University of Missouri, and PhD in Engineering from the University of Illinois, Chicago. He was also trained in the US Army, as a Physician Assistant, and worked (during those clinical years) in Ophthalmology and Emergency Medicine.
Though formally an engineering scientist, Dr. Moses possesses a substantial wealth of corporate knowledge and experience: he spent more than ten years developing his business skills in the disciplines of business development, strategic planning, organizational development, change and capture management and corporate visioning. And, finally, he possesses an enduring passion for the advancement of STEM education and STEM careers – especially amongst young children.
Jonas Moses, PhD PA, is the Director of Research and Clinical Director for the Mexico-based EnVision Eye Institute (www.ojos1.com). He also is a co-founder, former medical information officer and technical advisor to CYSEC LLC (www.cyberscureid.com), a Healthcare IT middleware cybersecurity company. Dr. Moses is a biomedical, scientific, and technical serial innovator. He has been awarded three US patents and has another dozen or more patents-pending. Moses’ career emphasis has been translational research, with professional experiences spanning academic, government and industrial laboratory research, technology transfer, scientific and technical liaising and commercialization of innovation. He has consulted with other scientists, governmental leaders, policy-makers, industry professionals and academes throughout the US, as well as in Europe, Asia and Latin America. He earned his undergraduate degree in Biology, from the University of Missouri, and PhD in Engineering from the University of Illinois, Chicago. He was also trained in the US Army, as a Physician Assistant, and worked (during those clinical years) in Ophthalmology and Emergency Medicine.
Though formally an engineering scientist, Dr. Moses possesses a substantial wealth of corporate knowledge and experience: he spent more than ten years developing his business skills in the disciplines of business development, strategic planning, organizational development, change and capture management and corporate visioning. And, finally, he possesses an enduring passion for the advancement of STEM education and STEM careers – especially amongst young children.
Jonathan Weiss
Principal Scientist, Kadmon
Dr. Jonathan Weiss has spent the past 5 years at Kadmon Pharmaceuticals ushering KD025, an inhibitor for the novel drug target ROCK2, from the lab into clinical trials. KD025 has received both Orphan Drug designation and Breakthrough Therapy designation from the FDA and is currently in a pivotal Phase IIb clinical trial. Jonathan completed his Ph.D. at the NYU School of Medicine and his M.B.A. at the NYU Stern School of Business.
Dr. Jonathan Weiss has spent the past 5 years at Kadmon Pharmaceuticals ushering KD025, an inhibitor for the novel drug target ROCK2, from the lab into clinical trials. KD025 has received both Orphan Drug designation and Breakthrough Therapy designation from the FDA and is currently in a pivotal Phase IIb clinical trial. Jonathan completed his Ph.D. at the NYU School of Medicine and his M.B.A. at the NYU Stern School of Business.
Jonathan Wicks
Behavioral Health Specialist/Trauma-Informed Care Coordinator, YWCA San Gabriel Valley
Jonathan M. Wicks is a clinician, musician, and entrepreneur. When he is not providing services to those exposed to traumatic experiences, he is busy cultivating young musicians into world class performers, while also finding the time to develop products and services in the tech space. He has traveled around the world as an entertainer, and looks forward to building a long-lasting global presence through clinical and business endeavors in the trauma and tech space.
(e.g. affective science, anger, behavioral health, biometrics, Bluetooth, digital networks, e-literature, mental health, neurobiology, racism, telehealth, virtual embodiment, virtual reality)
Jonathan M. Wicks is a clinician, musician, and entrepreneur. When he is not providing services to those exposed to traumatic experiences, he is busy cultivating young musicians into world class performers, while also finding the time to develop products and services in the tech space. He has traveled around the world as an entertainer, and looks forward to building a long-lasting global presence through clinical and business endeavors in the trauma and tech space.
(e.g. affective science, anger, behavioral health, biometrics, Bluetooth, digital networks, e-literature, mental health, neurobiology, racism, telehealth, virtual embodiment, virtual reality)
Joseph Oberlander
Research Scientist III and Group Leader, Baxter International
Dr. Joseph Oberlander is an inquisitive research scientist with broad training and technical expertise in neuronal cell biology, synaptic physiology, and pre-clinical animal models of CNS and endocrinology diseases. His background includes evaluation of CNS disease animal models and pharmacologic assessment of treatment candidates and medical device evaluation. His strengths include scientific project management, analytical method development, experimental design, and scientific writing. Joseph is also well-versed in computation and statistical analysis, including machine learning and data representation; he keeps abreast of the fast-paced technical literature in support of research priorities and interests, and he is a highly organized leader with excellent communication skills and ability to mentor and develop team members.
Joseph's journey from academia (post-docs at Dartmouth Medical School and Northwestern University) to industry (contract positions at Abbott Laboratories and Baxter Healthcare) has been exhilarating and eye-opening. He has taken on various roles at each stop, learned how to efficiently generate the necessary data to solve technical problems, and how to transition a product from discovery into development. In his time between positions, Joseph's passion for learning was forward-looking, in that he learned how to program statistical models for machine learning, and about the systematic management of projects from conception to completion. Joseph is trying to leverage his passion for learning, creativity, innovative thought processes, and robust problem-solving skills to bring some clarity to opaqueness of the central nervous system, and debilitating disorders when the underlying biology goes wrong.
Dr. Joseph Oberlander is an inquisitive research scientist with broad training and technical expertise in neuronal cell biology, synaptic physiology, and pre-clinical animal models of CNS and endocrinology diseases. His background includes evaluation of CNS disease animal models and pharmacologic assessment of treatment candidates and medical device evaluation. His strengths include scientific project management, analytical method development, experimental design, and scientific writing. Joseph is also well-versed in computation and statistical analysis, including machine learning and data representation; he keeps abreast of the fast-paced technical literature in support of research priorities and interests, and he is a highly organized leader with excellent communication skills and ability to mentor and develop team members.
Joseph's journey from academia (post-docs at Dartmouth Medical School and Northwestern University) to industry (contract positions at Abbott Laboratories and Baxter Healthcare) has been exhilarating and eye-opening. He has taken on various roles at each stop, learned how to efficiently generate the necessary data to solve technical problems, and how to transition a product from discovery into development. In his time between positions, Joseph's passion for learning was forward-looking, in that he learned how to program statistical models for machine learning, and about the systematic management of projects from conception to completion. Joseph is trying to leverage his passion for learning, creativity, innovative thought processes, and robust problem-solving skills to bring some clarity to opaqueness of the central nervous system, and debilitating disorders when the underlying biology goes wrong.
Kamayini Kaul
Head of Enterprise Data Lakes and Integrations, Bristol Myers Squibb
Kamayini Kaul joined Bristol-Myers Squibb in 2017 as the Global Head of Enterprise Data Lakes and Integrations.In her current role, she leads the global IT capabilities for BMS’s data lakes, master / reference data and middleware integrations platforms and applications. She is also a key lead in the execution of BMS’s digital health vision enabling faster drugs from discovery bench to patients with proven and targeted clinical outcomes.
Kamayini is known for her innovative and results-oriented approach and prior to joining BMS, has held positions of increasing levels of responsibility at large companies such as GE Healthcare, Santander Holdings, and Shire Pharmaceuticals.During her 16+ years of experience, she has held roles spanning from medical devices engineering to standing up enterprise wide capabilities around data management, governance and analytics.
Kamayini received her MBA in Marketing, Strategy & Entrepreneurship from Kellogg School of Business, in Chicago, IL.She also has an MS in Computer Science from the University of Chicago, and a BS in Computer Science from Illinois Institute of Technology.
Starting her journey in the corporate world as an engineer, she has always been an evangelist of corporate initiatives focused on Women in Technology, STEM and Diversity & Inclusion. She served as the Operations Leader for the GE Women’s Network NJ Hub and is an active member of the Healthcare Businesswomen’s Association of Boston and a former member of the Santander Women in Business Forum.
Kamayini Kaul joined Bristol-Myers Squibb in 2017 as the Global Head of Enterprise Data Lakes and Integrations.In her current role, she leads the global IT capabilities for BMS’s data lakes, master / reference data and middleware integrations platforms and applications. She is also a key lead in the execution of BMS’s digital health vision enabling faster drugs from discovery bench to patients with proven and targeted clinical outcomes.
Kamayini is known for her innovative and results-oriented approach and prior to joining BMS, has held positions of increasing levels of responsibility at large companies such as GE Healthcare, Santander Holdings, and Shire Pharmaceuticals.During her 16+ years of experience, she has held roles spanning from medical devices engineering to standing up enterprise wide capabilities around data management, governance and analytics.
Kamayini received her MBA in Marketing, Strategy & Entrepreneurship from Kellogg School of Business, in Chicago, IL.She also has an MS in Computer Science from the University of Chicago, and a BS in Computer Science from Illinois Institute of Technology.
Starting her journey in the corporate world as an engineer, she has always been an evangelist of corporate initiatives focused on Women in Technology, STEM and Diversity & Inclusion. She served as the Operations Leader for the GE Women’s Network NJ Hub and is an active member of the Healthcare Businesswomen’s Association of Boston and a former member of the Santander Women in Business Forum.
Kate Worthington
Principal, Next Phase Biotech Consulting
Your phase I/II study looks good: what now? Who do you need to talk to or hire? Dr. Kate Worthington can map that out with you. She's worked with small-, mid-, and large-pharma as they move their new therapies to the next phase. When do you need a full-time Sr Dir? What benefit is a medical affairs broad strategy? How far ahead do you need to look and did you need to start a process last year (okay, asap)? Talk to Kate.
Your phase I/II study looks good: what now? Who do you need to talk to or hire? Dr. Kate Worthington can map that out with you. She's worked with small-, mid-, and large-pharma as they move their new therapies to the next phase. When do you need a full-time Sr Dir? What benefit is a medical affairs broad strategy? How far ahead do you need to look and did you need to start a process last year (okay, asap)? Talk to Kate.
Katie Kirsch
CoFounder, Sisu Global Health
Katie Kirsch is a global marketing professional who excels at the intersection of industry, government and non-profits with a focus to increase opportunities for all. From education to healthcare, engineering to medicine, Katie's career thrives under the integration of multiple levels of thinking and creativity for better business development, profit and outcomes for business and organizations.
Katie Kirsch is a global marketing professional who excels at the intersection of industry, government and non-profits with a focus to increase opportunities for all. From education to healthcare, engineering to medicine, Katie's career thrives under the integration of multiple levels of thinking and creativity for better business development, profit and outcomes for business and organizations.
Katyaini Kathuria
Business Analyst, Marcelle Group
Katyaini Kathuria is a multilayered Business Analyst with extensive E-commerce and Startup experience across industries (textile, consumer goods, health care, hospitality) and functions (growth strategy, digital transformation, operations). She has demonstrated abilities in problem-solving and providing data-driven growth strategies and is a part of the start-up ecosystem in NYC. She received her MBA from Baruch College, U.S.A, MSc. in Analysis, Design and Management of Information Systems from London School of Economics, U.K and BSc. (Hons)in Management Sciences from University of Warwick, U.K.
Katyaini Kathuria is a multilayered Business Analyst with extensive E-commerce and Startup experience across industries (textile, consumer goods, health care, hospitality) and functions (growth strategy, digital transformation, operations). She has demonstrated abilities in problem-solving and providing data-driven growth strategies and is a part of the start-up ecosystem in NYC. She received her MBA from Baruch College, U.S.A, MSc. in Analysis, Design and Management of Information Systems from London School of Economics, U.K and BSc. (Hons)in Management Sciences from University of Warwick, U.K.
Kayla Chase
Medical Science Liaison, Collegium Pharma
Dr. Kayla Chase is an enthusiastic, creative and highly motivated molecular biologist with a strong work ethic and great communication skills. She is experienced in managing multiple projects and personnel simultaneously and thrives in a fast-paced environment. Kayla serves as Medical Science Liaison for Collegium Pharmaceutical and as Adjunct Professor at the School of the Art Institute of Chicago.
Dr. Kayla Chase is an enthusiastic, creative and highly motivated molecular biologist with a strong work ethic and great communication skills. She is experienced in managing multiple projects and personnel simultaneously and thrives in a fast-paced environment. Kayla serves as Medical Science Liaison for Collegium Pharmaceutical and as Adjunct Professor at the School of the Art Institute of Chicago.
Kevin Leslie
New Venture Manager, VCU Ventures
Kevin Leslie is a New Venture Manager with VCU Ventures where he works to build private-public funding partnerships and develop university-wide programs to accelerate research commercialization and train scientists in lean startup methodologies. He has over a decade of experience in academic research laboratories spanning the fields of microbiology, virology, cancer biophysics, and engineering. Prior to his current role, Kevin led strategy and oversight at a university spinout for the development of a novel molecular diagnostics technique with applications in cancer medicine and genetic disorders. He was recognized as the top performer in his cohort as his team’s Entrepreneurial Lead in the NSF’s I-Corps program and was invited to speak on the NIH’s inaugural I-Corps panel in Washington, DC. He earned his Ph.D. from Virginia Commonwealth University and his B.S. and M.S. from the College of William & Mary.
Kevin Leslie is a New Venture Manager with VCU Ventures where he works to build private-public funding partnerships and develop university-wide programs to accelerate research commercialization and train scientists in lean startup methodologies. He has over a decade of experience in academic research laboratories spanning the fields of microbiology, virology, cancer biophysics, and engineering. Prior to his current role, Kevin led strategy and oversight at a university spinout for the development of a novel molecular diagnostics technique with applications in cancer medicine and genetic disorders. He was recognized as the top performer in his cohort as his team’s Entrepreneurial Lead in the NSF’s I-Corps program and was invited to speak on the NIH’s inaugural I-Corps panel in Washington, DC. He earned his Ph.D. from Virginia Commonwealth University and his B.S. and M.S. from the College of William & Mary.
Lisa Friedlander
Business Development Manager, Shulman Rogers; Co-Founder, Activity Rocket
Lisa Friedlander was born and raised in Montgomery County, MD and after attending the University of Pennsylvania undergrad returned to DC to get her JD at The American University Washington College of Law.
Lisa practiced telecommunications and corporate law for nearly 15 years. After marrying Scott and having 3 kids – Jaclyn, Cole, and Camryn, Lisa became an entrepreneur co-founding Activity Rocket with her close friend Ilene Miller. Activity Rocket is an Expedia for Kids Classes, Camps & Sports. After building a full activity marketplace with over 700 activity providers and 100,000 activities listed, Activity Rocket was acquired by a west coast educational platform called Thrively. Thrively is a personalized strength-based learning platform building life skills, self-awareness, and promoting college/career readiness for students K-12. Lisa recently joined Shulman Rogers law firm as the Business Development Manager for the Business Group. She focuses on helping startups and emerging growth companies get to the next level. Lisa also founded The Heartsongs Luncheon Fund which raises money for Children’s National Health System. Heartsongs is in its 17th year and has raised well over $1,000,000 for the Hospital.
Lisa Friedlander was born and raised in Montgomery County, MD and after attending the University of Pennsylvania undergrad returned to DC to get her JD at The American University Washington College of Law.
Lisa practiced telecommunications and corporate law for nearly 15 years. After marrying Scott and having 3 kids – Jaclyn, Cole, and Camryn, Lisa became an entrepreneur co-founding Activity Rocket with her close friend Ilene Miller. Activity Rocket is an Expedia for Kids Classes, Camps & Sports. After building a full activity marketplace with over 700 activity providers and 100,000 activities listed, Activity Rocket was acquired by a west coast educational platform called Thrively. Thrively is a personalized strength-based learning platform building life skills, self-awareness, and promoting college/career readiness for students K-12. Lisa recently joined Shulman Rogers law firm as the Business Development Manager for the Business Group. She focuses on helping startups and emerging growth companies get to the next level. Lisa also founded The Heartsongs Luncheon Fund which raises money for Children’s National Health System. Heartsongs is in its 17th year and has raised well over $1,000,000 for the Hospital.
Luke Piggott
Translational Development Manager, Cardiff University
Dr. Luke Piggot is a project manager in business development at Cancer Research Technology (CRT), a commercialization and development company owned by Cancer Research UK, the world’s leading cancer charity. Prior to his role at CRT, Dr. Piggot served as the Translational Development Manager and a Drug Development Associate at Cardiff University, where he facilitated the translational development of cancer therapeutics from preclinical studies to commercialization and managed preclinical drug development for novel compounds. Dr. Piggot received his BS in Biochemistry and PhD in Breast Cancer Therapeutics from Cardiff University, where he also served as a STEM Ambassador and representative on the Genetic Modification and Biological Agents Safety and Ethical Committee.
Dr. Luke Piggot is a project manager in business development at Cancer Research Technology (CRT), a commercialization and development company owned by Cancer Research UK, the world’s leading cancer charity. Prior to his role at CRT, Dr. Piggot served as the Translational Development Manager and a Drug Development Associate at Cardiff University, where he facilitated the translational development of cancer therapeutics from preclinical studies to commercialization and managed preclinical drug development for novel compounds. Dr. Piggot received his BS in Biochemistry and PhD in Breast Cancer Therapeutics from Cardiff University, where he also served as a STEM Ambassador and representative on the Genetic Modification and Biological Agents Safety and Ethical Committee.
Malathi Narayan
Regulatory Specialist, Moffitt Cancer Center
Dr. Malathi Narayan is a regulatory specialist at the Moffitt Cancer Center. She has over 15 years of research experience in biochemistry and neuroscience at institutions such as the University of South Florida, Vanderbilt University, and the Medical College of Wisconsin. Dr. Narayan was awarded the American Association of Pharmaceutical Sciences Postdoctoral Fellowship and has contributed to over 13 peer reviewed publications, 2 patents, and a book chapter. She received her BS in Biological Sciences from the University of Buffalo and her PhD in Biochemistry from the Medical College of Wisconsin.
Dr. Malathi Narayan is a regulatory specialist at the Moffitt Cancer Center. She has over 15 years of research experience in biochemistry and neuroscience at institutions such as the University of South Florida, Vanderbilt University, and the Medical College of Wisconsin. Dr. Narayan was awarded the American Association of Pharmaceutical Sciences Postdoctoral Fellowship and has contributed to over 13 peer reviewed publications, 2 patents, and a book chapter. She received her BS in Biological Sciences from the University of Buffalo and her PhD in Biochemistry from the Medical College of Wisconsin.
Maleeha Qazi
Cancer Researcher & Medical Student, University of Toronto
Dr. Maleeha Qazi in an incoming medical student at the University of Toronto. She previously completed her PhD in Biochemistry and Biomedical Sciences at McMaster University and was the recipient of Canada Graduate Doctoralship by the Canadian Institute of Health Research. Maleeha's PhD thesis detailed the development of a personalized pre-clinical model for the identification of novel therapeutic targets against recurrent glioblastoma, the most common and aggressive primary brain cancer. She was awarded the Young Investigator Award by the Canadian Neuro-Oncology Society for excellence in translational neuro-oncology research and has been the recipient of multiple other research awards. Maleeha has a strong track record of academic publications and conference presentations in the field of brain cancer research and aims to now incorporate her research interests with medical training to improve treatments for patients with primary and metastatic brain cancer.
Dr. Maleeha Qazi in an incoming medical student at the University of Toronto. She previously completed her PhD in Biochemistry and Biomedical Sciences at McMaster University and was the recipient of Canada Graduate Doctoralship by the Canadian Institute of Health Research. Maleeha's PhD thesis detailed the development of a personalized pre-clinical model for the identification of novel therapeutic targets against recurrent glioblastoma, the most common and aggressive primary brain cancer. She was awarded the Young Investigator Award by the Canadian Neuro-Oncology Society for excellence in translational neuro-oncology research and has been the recipient of multiple other research awards. Maleeha has a strong track record of academic publications and conference presentations in the field of brain cancer research and aims to now incorporate her research interests with medical training to improve treatments for patients with primary and metastatic brain cancer.
Mamoon Khalid
Director of U.S. Ventures, Accathon Capital
Mamoon Ismail Khalid is currently leading the crossborder Venture Capital and accelerator arm of Accathon Capital.
Mamoon focuses on investments in Cyber Security, FinTech, Computer Vision, Artificial Intelligence/Machine Learning, Drone technologies, VR/AR and SaaS. Prior to entering Venture Capital, Mamoon led product development and strategy execution for three venture capital backed startups based in NYC. A Computer Engineer at heart with two engineering degrees under his belt, he has previously also served as the Research Lead for a 16-member R&D team in a NFL/NYU Langone Medical Center project, for which he explored the use of machine learning solutions in the treatment of autism and epilepsy detection; as well as symptom analytics. While a Masters candidate at NYU, he also authored a major journal paper publication on the automated tracking and quantification of a Microsoft Kinect-based Concussion Monitoring System by developing state-of-the-art facial recognition and body motion mapping algorithms. His work got featured in the 22nd Medicine Meets Virtual Reality Conference, Florida (2016).
An advocate for clean energy and smart energy storage/consumption technologies, Mamoon has a special passion for driving strategic growth and business development for startups focused on renewable energy and reforestation. Previously Mamoon has researched solutions for enhancing large-scale renewable energy storage battery lives by up to 300% through device analytics and proprietary (patent pending) optimization algorithms. He holds a green belt in Kyokushin karate and enjoys a competitive game of Squash.
Mamoon Ismail Khalid is currently leading the crossborder Venture Capital and accelerator arm of Accathon Capital.
Mamoon focuses on investments in Cyber Security, FinTech, Computer Vision, Artificial Intelligence/Machine Learning, Drone technologies, VR/AR and SaaS. Prior to entering Venture Capital, Mamoon led product development and strategy execution for three venture capital backed startups based in NYC. A Computer Engineer at heart with two engineering degrees under his belt, he has previously also served as the Research Lead for a 16-member R&D team in a NFL/NYU Langone Medical Center project, for which he explored the use of machine learning solutions in the treatment of autism and epilepsy detection; as well as symptom analytics. While a Masters candidate at NYU, he also authored a major journal paper publication on the automated tracking and quantification of a Microsoft Kinect-based Concussion Monitoring System by developing state-of-the-art facial recognition and body motion mapping algorithms. His work got featured in the 22nd Medicine Meets Virtual Reality Conference, Florida (2016).
An advocate for clean energy and smart energy storage/consumption technologies, Mamoon has a special passion for driving strategic growth and business development for startups focused on renewable energy and reforestation. Previously Mamoon has researched solutions for enhancing large-scale renewable energy storage battery lives by up to 300% through device analytics and proprietary (patent pending) optimization algorithms. He holds a green belt in Kyokushin karate and enjoys a competitive game of Squash.
Marco Morales
Entrepreneur and Independent Consultant
Marco Morales is a passionate clinician, scientist and serial entrepreneur.
Clinical Research Strategist for Phases 0-I-II-III in Pharmaceuticals, Biologics, Medical Devices, IVDs.
Goal: Move forward ideas to companies and scientific innovation to market.
International Consultant, Translational Technology Strategist in Medical Devices, Biotech, Biologics, Medicine, Business Development, Intellectual Property Strategist, Technology Transfer, International Regulatory Pathways, Lead Projects Management of International Multicultural Technology Research Teams for Development and Innovation.
Regulatory Affairs and Q/A, Strategist for US and Mexico for Pre-Clinical, Clinical Phases 0-I-II-III, Clinical Trials, Pharmaceuticals, Medical Devices, Biologics, In Vitro Diagnostics, GMP, Auditing, Monitoring, Labeling, Packaging, International Logistics. ICH GCP E6 (R2) Good Clinical Practice Certified.
Biotech/Medtech Business Model Strategist for Innovation, Budgets, M&A, Non-Dilution Funding strategist, Biotech/Medtech Equities Analyst, Valuations, Bloomberg Certified.
Marco Morales is a passionate clinician, scientist and serial entrepreneur.
Clinical Research Strategist for Phases 0-I-II-III in Pharmaceuticals, Biologics, Medical Devices, IVDs.
Goal: Move forward ideas to companies and scientific innovation to market.
International Consultant, Translational Technology Strategist in Medical Devices, Biotech, Biologics, Medicine, Business Development, Intellectual Property Strategist, Technology Transfer, International Regulatory Pathways, Lead Projects Management of International Multicultural Technology Research Teams for Development and Innovation.
Regulatory Affairs and Q/A, Strategist for US and Mexico for Pre-Clinical, Clinical Phases 0-I-II-III, Clinical Trials, Pharmaceuticals, Medical Devices, Biologics, In Vitro Diagnostics, GMP, Auditing, Monitoring, Labeling, Packaging, International Logistics. ICH GCP E6 (R2) Good Clinical Practice Certified.
Biotech/Medtech Business Model Strategist for Innovation, Budgets, M&A, Non-Dilution Funding strategist, Biotech/Medtech Equities Analyst, Valuations, Bloomberg Certified.
Margeaux Anderson
Customer Success Manager, Artifact Health, Johns Hopkins University
Margeaux Anderson is currently the Customer Success Manager at Artifact Health, a company dedicated to creating and implementing IT solutions for healthcare organizations. She has extensive experience in operations, strategy, and customer service from her project management roles in healthcare and manufacturing, in addition to technical experience as an engineer for an environmental services firm. She received her Bachelor’s in Environmental Engineering from Northern Arizona University and is pursuing her Master’s in Business Administration from John Hopkins University.
Margeaux Anderson is currently the Customer Success Manager at Artifact Health, a company dedicated to creating and implementing IT solutions for healthcare organizations. She has extensive experience in operations, strategy, and customer service from her project management roles in healthcare and manufacturing, in addition to technical experience as an engineer for an environmental services firm. She received her Bachelor’s in Environmental Engineering from Northern Arizona University and is pursuing her Master’s in Business Administration from John Hopkins University.
Megan Peppenelli
Postdoctoral Research Fellow, University of Arizona
Megan Peppenelli, PhD is passionate about scientific communication and advocating for science with the public. She graduated from Syracuse University at Utica College with a BS in biology and continued on to complete a PhD at Upstate Medical University in Microbiology and Immunology. As a viral immunologist she has a deep desire to help educate the public on topics such as stem cell research, vaccines and disease.
Megan Peppenelli, PhD is passionate about scientific communication and advocating for science with the public. She graduated from Syracuse University at Utica College with a BS in biology and continued on to complete a PhD at Upstate Medical University in Microbiology and Immunology. As a viral immunologist she has a deep desire to help educate the public on topics such as stem cell research, vaccines and disease.
Melinda Barkhuizen
External Consultant, Maastricht University
Dr. Melinda Barkhuizen is a research consultant at Maastricht UMC+, an academic hospital in Maastricht, Netherlands. Prior to her time at Maastricht UMC+, she performed postdoctoral research at the University of California San Francisco where she also served as a board member of the UCSF Postdoctoral Scholar Association. Dr. Barkhuizen received her Ph.D. in Pharmaceutical Sciences jointly from Maastricht University in the Netherlands and North-West University in South Africa.
Dr. Melinda Barkhuizen is a research consultant at Maastricht UMC+, an academic hospital in Maastricht, Netherlands. Prior to her time at Maastricht UMC+, she performed postdoctoral research at the University of California San Francisco where she also served as a board member of the UCSF Postdoctoral Scholar Association. Dr. Barkhuizen received her Ph.D. in Pharmaceutical Sciences jointly from Maastricht University in the Netherlands and North-West University in South Africa.
Michael Wood
Founder & COO, OncoMyx Therapeutics
Michael Wood is the founder and Chief Operating Officer of OncoMyx Therapeutics, an oncolytic immunotherapy company dedicated to developing cancer therapeutics. In addition to his experience at OncoMyx, Michael has an extensive background in business development in the pharmaceutical sector. He has served as Vice President of Corporate Development & Operations at Crinetics Pharmaceuticals and in business development roles in aTyr Pharma, Orexigen Therapeutics, and Abbot Laboratories. Michael began his business background working in business working as a management consultant at Tenet Healthcare and an investment banker at Morgan Stanley. Beyond his business background, Michael also has extensive research experience in scientific labs at the University of California San Francisco, University of California Berkeley, and the Salk Research Institute. He received his MBA from the Booth School of Business at the University of Chicago and his Bachelor’s in Molecular and Cell Biology from the University of California Berkeley.
Michael Wood is the founder and Chief Operating Officer of OncoMyx Therapeutics, an oncolytic immunotherapy company dedicated to developing cancer therapeutics. In addition to his experience at OncoMyx, Michael has an extensive background in business development in the pharmaceutical sector. He has served as Vice President of Corporate Development & Operations at Crinetics Pharmaceuticals and in business development roles in aTyr Pharma, Orexigen Therapeutics, and Abbot Laboratories. Michael began his business background working in business working as a management consultant at Tenet Healthcare and an investment banker at Morgan Stanley. Beyond his business background, Michael also has extensive research experience in scientific labs at the University of California San Francisco, University of California Berkeley, and the Salk Research Institute. He received his MBA from the Booth School of Business at the University of Chicago and his Bachelor’s in Molecular and Cell Biology from the University of California Berkeley.
Moustapha El-Amine
Director Global Search and Evaluate, AstraZeneca
Dr. Moustapha El-Amine leads strategic partnering and business development at AstraZeneca, where he is responsible for the following:
Generating deal flow through the identification, initial business fit and scientific evaluation of potential strategic opportunities
Leading therapeutic area and technology focused sourcing projects aimed at identifying in-licensing and/or acquisition opportunities
Sourcing and leading matrixed teams comprising major R&D functions as well as corporate functions, to assess and evaluate internal and external assets for potential investment.
Providing oversight of R&D pipeline, identifying novel therapeutics and program prioritization
Identifying, late-stage and commercial assets that potentially fill portfolio gaps and leading partnering negotiations
Dr. Moustapha El-Amine leads strategic partnering and business development at AstraZeneca, where he is responsible for the following:
Generating deal flow through the identification, initial business fit and scientific evaluation of potential strategic opportunities
Leading therapeutic area and technology focused sourcing projects aimed at identifying in-licensing and/or acquisition opportunities
Sourcing and leading matrixed teams comprising major R&D functions as well as corporate functions, to assess and evaluate internal and external assets for potential investment.
Providing oversight of R&D pipeline, identifying novel therapeutics and program prioritization
Identifying, late-stage and commercial assets that potentially fill portfolio gaps and leading partnering negotiations
Nabila Founounou
Fellow, Mount Sinai Innovation Partners
Dr. Nabila Founounou has experience in basic science, which started as an undergraduate student in Dr. Noselli’s Laboratory, where she studied the role of microtubules in mRNA asymmetric localization of JAK/STAT pathway ligand during polarized invasive cell migration. For her PhD, Nabila joined Dr. Le Borgne’s team to study asymmetric cell division and Notch signaling-dependent cell fate decision. Nabila’s work showed that the small GTPases, Septins, are involved in a mechanical role to overcome the tension of adhesive contacts during planar cytokinesis in epithelial cells. Her work demonstrates that the defect in cell fate acquisition is an indirect consequence of differential cytokinesis failure. To date, Nabila’s studies have touched on cell signaling, regulation of adhesive contacts and cytoskeleton dynamics during cell migration in a developmental context. Moving forward, Nabila is keen to use her background to focus on understanding how biochemical signals are translated into mechanical ones during large-scale morphogenetic processes combining classical genetics with biophysical approaches and quantitative live imaging analysis. Specifically, how planar polarity mobilizes the cytoskeleton to promote cell movements and how these movements are transmitted within the tissue.
Dr. Nabila Founounou has experience in basic science, which started as an undergraduate student in Dr. Noselli’s Laboratory, where she studied the role of microtubules in mRNA asymmetric localization of JAK/STAT pathway ligand during polarized invasive cell migration. For her PhD, Nabila joined Dr. Le Borgne’s team to study asymmetric cell division and Notch signaling-dependent cell fate decision. Nabila’s work showed that the small GTPases, Septins, are involved in a mechanical role to overcome the tension of adhesive contacts during planar cytokinesis in epithelial cells. Her work demonstrates that the defect in cell fate acquisition is an indirect consequence of differential cytokinesis failure. To date, Nabila’s studies have touched on cell signaling, regulation of adhesive contacts and cytoskeleton dynamics during cell migration in a developmental context. Moving forward, Nabila is keen to use her background to focus on understanding how biochemical signals are translated into mechanical ones during large-scale morphogenetic processes combining classical genetics with biophysical approaches and quantitative live imaging analysis. Specifically, how planar polarity mobilizes the cytoskeleton to promote cell movements and how these movements are transmitted within the tissue.
Oleg Kolupaev
Transplantation/Cancer Immunology Researcher, University of North Carolina at Chapel Hill
Dr. Oleg Kolupaev is an immunolovy post-doctorate research associate at the UNC Lineberger Comprehensive Cancer Center. The aim of his current research is to understand the role of B cells in the pathogenesis of chronic graft-versus-host disease using mouse models. Previously, he served as an entrepreneurship intern at the UNC Eshelman School of Pharmacy and as an intern for the Office of Technology Development.
Dr. Oleg Kolupaev is an immunolovy post-doctorate research associate at the UNC Lineberger Comprehensive Cancer Center. The aim of his current research is to understand the role of B cells in the pathogenesis of chronic graft-versus-host disease using mouse models. Previously, he served as an entrepreneurship intern at the UNC Eshelman School of Pharmacy and as an intern for the Office of Technology Development.
Pawel Buczkowicz
COO & VP Scientific & Medical Affairs, Gene42
Dr. Pawel Buczkowicz has Lean Six Sigma certification and a PhD in cancer genetics and molecular pathology from the University of Toronto. He has worked on various projects including using next generation sequencing technologies to improve therapies for high-risk childhood cancer, development and validation of clinical genetic tests, and translational research on paediatric stroke, vasculitis and brain tumours. Based on his translational research on brainstem gliomas, published in various high impact journals such as Nature Genetics, including the discovery of novel mutations in human cancers and development of clinical correlates, a new World Health Organization classification was implemented for paediatric gliomas. Dr. Buczkowicz is passionate about streamlining clinical workflows in order to improve the healthcare experience for both patient and doctor and believes smart and efficient software will revolutionize the way medicine is practiced.
Dr. Pawel Buczkowicz has Lean Six Sigma certification and a PhD in cancer genetics and molecular pathology from the University of Toronto. He has worked on various projects including using next generation sequencing technologies to improve therapies for high-risk childhood cancer, development and validation of clinical genetic tests, and translational research on paediatric stroke, vasculitis and brain tumours. Based on his translational research on brainstem gliomas, published in various high impact journals such as Nature Genetics, including the discovery of novel mutations in human cancers and development of clinical correlates, a new World Health Organization classification was implemented for paediatric gliomas. Dr. Buczkowicz is passionate about streamlining clinical workflows in order to improve the healthcare experience for both patient and doctor and believes smart and efficient software will revolutionize the way medicine is practiced.
Rahul Nandre
Staff Scientist, Henry M. Jackson Foundation for the Advancement of Military Medicine
Dr. Rahul Nandre is an experienced Microbiologist and Immunologist with a demonstrated history of working in the academics with industry based projects. He is skilled in Clinical Microbiology, Vaccine development, Vaccine induced immunology, Onco-immunology, Veterinary Medicine, Good Laboratory Practice (GLP), Vaccines, Molecular Biology, and Biotechnology.
Dr. Rahul Nandre is an experienced Microbiologist and Immunologist with a demonstrated history of working in the academics with industry based projects. He is skilled in Clinical Microbiology, Vaccine development, Vaccine induced immunology, Onco-immunology, Veterinary Medicine, Good Laboratory Practice (GLP), Vaccines, Molecular Biology, and Biotechnology.
Raja Krishnan
Commercialization Manager, University of Kentucky
Raja Krishan is a leader in business development and commercialization specializing in the pharmaceutical industry. He is currently the Life Sciences Licensing Manager in the Office of Technology Commercialization at the University of Kentucky and serves as an advisor to a number of biotech startups including Great Lakes Neuroscience, Therapalz, and Corvae. Raja has over 15 years of technical experience as an engineer at companies such as URL Pharma, Patheon Pharmaceuticals, and Schering-Plough. He received his Master’s of Science in Law from Northwestern University, Master’s in Business Administration from the University of Notre Dame, Master’s in Pharmaceutics from Long Island University, and Bachelor’s in Chemical Engineering from Cornell University.
Raja Krishan is a leader in business development and commercialization specializing in the pharmaceutical industry. He is currently the Life Sciences Licensing Manager in the Office of Technology Commercialization at the University of Kentucky and serves as an advisor to a number of biotech startups including Great Lakes Neuroscience, Therapalz, and Corvae. Raja has over 15 years of technical experience as an engineer at companies such as URL Pharma, Patheon Pharmaceuticals, and Schering-Plough. He received his Master’s of Science in Law from Northwestern University, Master’s in Business Administration from the University of Notre Dame, Master’s in Pharmaceutics from Long Island University, and Bachelor’s in Chemical Engineering from Cornell University.
Reginald Swift
Founder & CEO, Rubix LS
Reginald Swift is CEO and high energy engineer of Rubix LS - a place where we can reimagine a world where we close the gaps of health disparities and opportunities by forging breakthrough science and bridges where everyone deserves a chance to be saved by a cure. Reginald uses engineering as the paintbrush where healthcare is his canvas.
Reginald Swift is CEO and high energy engineer of Rubix LS - a place where we can reimagine a world where we close the gaps of health disparities and opportunities by forging breakthrough science and bridges where everyone deserves a chance to be saved by a cure. Reginald uses engineering as the paintbrush where healthcare is his canvas.
Richa Singhania
Director, Cerebral Organoid Translational Core, Weill Cornell Medicine
Dr. Richa Singhania spearheads the Cerebral Organoid Translational Core at Weill Cornell Medicine to integrate latest advancements in automation and organoid technology and to create personalized solutions for brain cancer patients.
• Over 10 years of oncology research experience at premier academic institutions in USA, UK and Australia
• Published 8 manuscripts in leading scientific journals and presented research findings at more than 10 international conferences
• Mentored and trained several postdocs and students. Conducted lectures for several Molecular Bioscience courses
Areas of expertise:
Cancer signaling I Stem cell biology I Human Genetics I Gene function and regulation I RNA Biochemistry
Human stem cell derivation, culture and differentiation I iPSC reprogramming I Organoid technology and 3D culture systems I CRISPR/Cas9 and RNAi tools | 2D/3D HTS assay development and testing I Primary patient-derived cell line generation I Mechanism of action experiments and target validation I Single-cell RNA sequencing | Advanced fluorescent imaging I
Dr. Richa Singhania spearheads the Cerebral Organoid Translational Core at Weill Cornell Medicine to integrate latest advancements in automation and organoid technology and to create personalized solutions for brain cancer patients.
• Over 10 years of oncology research experience at premier academic institutions in USA, UK and Australia
• Published 8 manuscripts in leading scientific journals and presented research findings at more than 10 international conferences
• Mentored and trained several postdocs and students. Conducted lectures for several Molecular Bioscience courses
Areas of expertise:
Cancer signaling I Stem cell biology I Human Genetics I Gene function and regulation I RNA Biochemistry
Human stem cell derivation, culture and differentiation I iPSC reprogramming I Organoid technology and 3D culture systems I CRISPR/Cas9 and RNAi tools | 2D/3D HTS assay development and testing I Primary patient-derived cell line generation I Mechanism of action experiments and target validation I Single-cell RNA sequencing | Advanced fluorescent imaging I
Robert Ferry
Endo4Life, Founder & President
Dr. Robert Ferry is a dynamic veteran physician with an exemplary record of inspiring others, leading innovation, enhancing quality of care, driving safety initiatives, streamlining institutional operations, expanding clinical volume and staff, and controlling costs. He demonstrates abilities to partner with divergent stakeholders to achieve enterprise goals under budget and on time. He is a servant-leader and responsive decision-maker who seeks feedback, embraces challenges, and supports diversity.
Dr. Robert Ferry is a dynamic veteran physician with an exemplary record of inspiring others, leading innovation, enhancing quality of care, driving safety initiatives, streamlining institutional operations, expanding clinical volume and staff, and controlling costs. He demonstrates abilities to partner with divergent stakeholders to achieve enterprise goals under budget and on time. He is a servant-leader and responsive decision-maker who seeks feedback, embraces challenges, and supports diversity.
Robert Martone
Principal Scientist, Biogen
Robert Martone is an accomplished scientist with 20 years of industry and 10 years of academic research experience. He is currently a principal scientist as Biogen and has extensive research experience in a several leading healthcare and pharmaceutical organizations such as St. Jude’s Children’s Research Hospital, Covance, and Wyeth (now apart of Pfizer). Robert received his Bachelor’s in Biology from the University of Albany and studied Anatomy and Neurobiology in the Larner College of Medicine at the University of Vermont.
Robert Martone is an accomplished scientist with 20 years of industry and 10 years of academic research experience. He is currently a principal scientist as Biogen and has extensive research experience in a several leading healthcare and pharmaceutical organizations such as St. Jude’s Children’s Research Hospital, Covance, and Wyeth (now apart of Pfizer). Robert received his Bachelor’s in Biology from the University of Albany and studied Anatomy and Neurobiology in the Larner College of Medicine at the University of Vermont.
Robert Overbaugh
Medical Director, Pain Management Services, Cancer Treatment Centers of America
Dr. Robert Overbaugh joined Cancer Treatment Centers of America® (CTCA) in September 2017. He is the Medical Director, Pain Management Services at our hospital in Philadelphia, Pennsylvania.
Working in the Quality of Life Center, Dr. Overbaugh will be providing pain management services to patients with all cancer types. He has had extensive experience working with integrative pain management, including acupuncture, chiropractic, rehabilitation, nutrition and others. “I am especially excited to continue working with an interdisciplinary team using a whole-person approach to pain management,” Dr. Overbaugh says. “My goal is to empower our patients to have a true choice in the management of their pain by giving them the tools and opportunities to do so.”
Dr. Overbaugh continues to seek out opportunities to learn about new tools and technologies for pain management. He has a special interest in cryo-neuroablation, which is a technique that utilizes freezing and destruction of painful peripheral nerves under ultrasound guidance. Additionally, he has a clinical interest in kyphoplasty to alleviate pain from metastatic disease to the spine.
Dr. Overbaugh completed his Bachelor of Science degree in biological sciences and graduated Magna Cum Laude from the University of Notre Dame. He then received his Doctorate of Medicine from Pennsylvania State University College of Medicine in Hershey, Pennsylvania. Dr. Overbaugh completed an anesthesiology residency at Brooke Army Medical Center and a pain medicine fellowship at Pennsylvania State University.
With over 16 years of experience in the practice of interventional pain management, Dr. Overbaugh is board certified in both pain medicine and anesthesiology by the American Board of Anesthesiology. He has published myriad peer-reviewed articles, abstracts and textbook chapters on topics in pain medicine. He has held academic appointments at several institutions, including the University of New Mexico, the University of Texas Health Science Center and the Uniformed Services University in Bethesda.
When he isn’t practicing medicine, Dr. Overbaugh enjoys motorcycling, marksmanship and spending time with his wife Kristen. As a retired soldier, he is also actively involved in caring for our nation’s veterans and their families.
Dr. Robert Overbaugh joined Cancer Treatment Centers of America® (CTCA) in September 2017. He is the Medical Director, Pain Management Services at our hospital in Philadelphia, Pennsylvania.
Working in the Quality of Life Center, Dr. Overbaugh will be providing pain management services to patients with all cancer types. He has had extensive experience working with integrative pain management, including acupuncture, chiropractic, rehabilitation, nutrition and others. “I am especially excited to continue working with an interdisciplinary team using a whole-person approach to pain management,” Dr. Overbaugh says. “My goal is to empower our patients to have a true choice in the management of their pain by giving them the tools and opportunities to do so.”
Dr. Overbaugh continues to seek out opportunities to learn about new tools and technologies for pain management. He has a special interest in cryo-neuroablation, which is a technique that utilizes freezing and destruction of painful peripheral nerves under ultrasound guidance. Additionally, he has a clinical interest in kyphoplasty to alleviate pain from metastatic disease to the spine.
Dr. Overbaugh completed his Bachelor of Science degree in biological sciences and graduated Magna Cum Laude from the University of Notre Dame. He then received his Doctorate of Medicine from Pennsylvania State University College of Medicine in Hershey, Pennsylvania. Dr. Overbaugh completed an anesthesiology residency at Brooke Army Medical Center and a pain medicine fellowship at Pennsylvania State University.
With over 16 years of experience in the practice of interventional pain management, Dr. Overbaugh is board certified in both pain medicine and anesthesiology by the American Board of Anesthesiology. He has published myriad peer-reviewed articles, abstracts and textbook chapters on topics in pain medicine. He has held academic appointments at several institutions, including the University of New Mexico, the University of Texas Health Science Center and the Uniformed Services University in Bethesda.
When he isn’t practicing medicine, Dr. Overbaugh enjoys motorcycling, marksmanship and spending time with his wife Kristen. As a retired soldier, he is also actively involved in caring for our nation’s veterans and their families.
Russell Hagan
Independent Consultant
Russell Hagan has over 30 Years Pharmaceutical and Medtech Industry experience in R&D, Business Development & IP Licensing and Commercial Strategy. Specialties: Oncology & Neuroscience.
Russell Hagan has over 30 Years Pharmaceutical and Medtech Industry experience in R&D, Business Development & IP Licensing and Commercial Strategy. Specialties: Oncology & Neuroscience.
Saman Mirzaei
Scientist, UC Irvine School of Medicine
Dr. Saman Mirzaei is a focused and dedicated Research Specialist at University of California, Irvine, with over 4 years’ experience in biomedical research (molecular, clinical and translational studies) with advanced knowledge of multiple therapeutic areas: Pharmacogenomics, Biomarkers, Clinical diagnostic, Mitochondria and Molecular genetics. Her major research focus is on understanding the molecular mechanisms that lead to chronic disease and also determining diagnostic markers for diabetic nephropathy.
Dr. Saman Mirzaei is a focused and dedicated Research Specialist at University of California, Irvine, with over 4 years’ experience in biomedical research (molecular, clinical and translational studies) with advanced knowledge of multiple therapeutic areas: Pharmacogenomics, Biomarkers, Clinical diagnostic, Mitochondria and Molecular genetics. Her major research focus is on understanding the molecular mechanisms that lead to chronic disease and also determining diagnostic markers for diabetic nephropathy.
Sanjeev Thohan
Senior Director Preclinical, Xeris Pharmaceuticals
Sanjeev Thohan is a highly motivated research scientist who with every move has sought new challenges to overcome with each career-based move. He holds MS and PhD degrees in Pharmacology and Toxicology with concentrations in drug metabolism mechanisms, bioactivation pathways, and systems toxicology. He has actively contributed to: preparation of Pre-IND/IND, NDA and proof of concept documentation to support regulatory filings as preclinical development continues; inter-species scaling and projection of FIM dosage algorithm development; metabolic pathway elucidation and structural (SAR) feedback to medicinal chemistry for additional iterations based on biological data streams; high throughput bioanalytical method development/transfer, as well as troubleshooting for rapid method development/implementation. He has also led teams for evaluation of strategic critical pathway development, implementation and execution to provide data frontloading and reduction in time to IND. He is a highly motivated research scientist who has worked at Walter Reed Army Institute for Research, Covance Laboratories, AstraZeneca, Viropharma, Exelixis and as the founder of SARx Consulting and it currently at Novartis in Cambridge, MA. Sanjeev’s track record includes advancement of 33 small molecule compounds through discovery to IND and various stages of active clinical development since 1997 with three of these progressing to NDA. Therapeutic areas in which he has been actively involved are oncology, cardiovascular, metabolic diseases and antimicrobial, as well as antiviral therapeutic areas.
Sanjeev Thohan is a highly motivated research scientist who with every move has sought new challenges to overcome with each career-based move. He holds MS and PhD degrees in Pharmacology and Toxicology with concentrations in drug metabolism mechanisms, bioactivation pathways, and systems toxicology. He has actively contributed to: preparation of Pre-IND/IND, NDA and proof of concept documentation to support regulatory filings as preclinical development continues; inter-species scaling and projection of FIM dosage algorithm development; metabolic pathway elucidation and structural (SAR) feedback to medicinal chemistry for additional iterations based on biological data streams; high throughput bioanalytical method development/transfer, as well as troubleshooting for rapid method development/implementation. He has also led teams for evaluation of strategic critical pathway development, implementation and execution to provide data frontloading and reduction in time to IND. He is a highly motivated research scientist who has worked at Walter Reed Army Institute for Research, Covance Laboratories, AstraZeneca, Viropharma, Exelixis and as the founder of SARx Consulting and it currently at Novartis in Cambridge, MA. Sanjeev’s track record includes advancement of 33 small molecule compounds through discovery to IND and various stages of active clinical development since 1997 with three of these progressing to NDA. Therapeutic areas in which he has been actively involved are oncology, cardiovascular, metabolic diseases and antimicrobial, as well as antiviral therapeutic areas.
Sayyed Ahmad Masud
CEO, Change Mechanics Pvt Ltd
Sayyed Ahmad Masud is the managing director of Channel 7 Communications, where he has three decades of experience in marketing and brand development. He is also involved in a number of entrepreneurial organizations catering to start ups and new business ventures. He currently serves as the CEO for Change Mechanics, the managing partner for Launchpad Interactive, the Islamabad Director for The Founder Institute, a mentor for the National Incubation Center, and a member on the Board of Advisors for the Takleeq Incubation Center. Sayyed received his Master’s in Business Administration from Quaid-e-Azam University and his Bachelor of Commerce from the Islamabad College of Commerce.
Sayyed Ahmad Masud is the managing director of Channel 7 Communications, where he has three decades of experience in marketing and brand development. He is also involved in a number of entrepreneurial organizations catering to start ups and new business ventures. He currently serves as the CEO for Change Mechanics, the managing partner for Launchpad Interactive, the Islamabad Director for The Founder Institute, a mentor for the National Incubation Center, and a member on the Board of Advisors for the Takleeq Incubation Center. Sayyed received his Master’s in Business Administration from Quaid-e-Azam University and his Bachelor of Commerce from the Islamabad College of Commerce.
Shelly Kaushik
Scientist, University of California, San Francisco
Dr. Shelly Kaushik has 10 years of cancer biology experience, including 2 years in industry, in cell-based, mouse and patient-derived brain and breast tumor models. Project leader in biology and part of multiple cross-functional teams, driving drug discovery and preclinical experimental therapeutics. Expertise in designing and executing cell-based assays and advanced cell culture techniques, immune-compromised and competent mouse tumor models, advanced microscopy, biochemistry and molecular biology techniques. Excellent communicator and team player with more than 8 years of mentorship, collaborative, scientific writing and publishing experience in industry and academia.
Dr. Shelly Kaushik has 10 years of cancer biology experience, including 2 years in industry, in cell-based, mouse and patient-derived brain and breast tumor models. Project leader in biology and part of multiple cross-functional teams, driving drug discovery and preclinical experimental therapeutics. Expertise in designing and executing cell-based assays and advanced cell culture techniques, immune-compromised and competent mouse tumor models, advanced microscopy, biochemistry and molecular biology techniques. Excellent communicator and team player with more than 8 years of mentorship, collaborative, scientific writing and publishing experience in industry and academia.
Silvana Nani
CEO, Korabi Consulting
Silvana Nani is a senior level executive and consultant with over 15 years of experience in private and public sector business development. She is currently the management and IT advisor for Korabi Consulting, focusing on utilizing advances in artificial intelligence to improve anti-fraud and risk management in the Fintech space. She has served as a consultant to a variety of organizations, including the US Department of the Treasury, the US Department of Justice, AARP, and Booz Allen Hamilton. She has also provided leadership to organizations, acting as the Chief Operating Officer for the Software Revolution and the Vice President of Marketing for Domus USA. Silvana received her Master’s in International Management from the University of Maryland University College.
Silvana Nani is a senior level executive and consultant with over 15 years of experience in private and public sector business development. She is currently the management and IT advisor for Korabi Consulting, focusing on utilizing advances in artificial intelligence to improve anti-fraud and risk management in the Fintech space. She has served as a consultant to a variety of organizations, including the US Department of the Treasury, the US Department of Justice, AARP, and Booz Allen Hamilton. She has also provided leadership to organizations, acting as the Chief Operating Officer for the Software Revolution and the Vice President of Marketing for Domus USA. Silvana received her Master’s in International Management from the University of Maryland University College.
Simone Azevedo
- Owner, USH Consulting
Simone Azevedo, is the owner of USH Consulting LLC/US4RARE.
Simone Azevedo has more than 25 years of experience in rare diseases with extensive global experience. Simone led several global rare diseases programs at Genzyme/Sanofi with P&L responsibility and working across multi-functional teams. She also led Genzyme’s global Humanitarian Programs providing access to treatment in over 80 countries. Still at Genzyme, Simone joined the Emerging Markets before deciding to change her career from commercial roles to focus on advocacy and patient services when she joined Bioverativ (Biogen’s spinoff for hemophilia) in January 2017. In 2018 Sanofi acquired Bioverativ and Simone became the Global Head of Public Affairs for Rare Blood Disorders.
Simone now has her own consulting company focusing on Rare Diseases and is particularly interested in sustainability, access and how to get biotechs committed to these areas.
Siva Narayanan
- President and Global Head, Pointe Health
A strategist and leader with over two decades of experience in formulating commercialization and patient access strategies through market/stakeholder focus, research excellence and strategy support. Proven leader and team builder with business and clinical backgrounds.
Built a strong career and leadership in commercial/medical strategies, market access, value/evidence and health policy within Pharma/Biotech industry through tenures at PTC Therapeutics (orphan diseases), Human Genome Sciences/GSK (orphan disease & immunology), BMS (oncology & immunology) and Merck & Co. (CNS, ID & respiratory) covering US & Ex-US segments. At PTC, as VP and Global Head, led market access, pricing and value creation department covering Americas, Europe, MENA & APAC.
In the strategy consulting arena, Siva held SVP roles at DRG, TNS Healthcare/Kantar and Ipsos Healthcare leading relevant divisions and client strategies to help clients create commercial and scientific strategies and patient access solutions, articulate product value propositions and achieve optimal access in the U.S and Ex-U.S. Within healthcare provider sector, Siva led clinical and strategic evaluations across a spectrum of LTC services at Beverly Enterprises; he also served in their Pharmacy Quality council (P&T Committee).
Currently Siva serves as the President and Global Head of Pointe Health, a subsidiary of Pointe Advisory.
Stefanie Mazlish
- CEO, TSL: The Solution Lab
Stefanie Mazlish is Co-founder and CEO of The Solution Lab, a nonprofit which develops creative solutions for healthcare, pharmaceutical, and biotech companies facing strategic and operational challenges. The Solution Lab forms interdisciplinary teams of students and recent graduates with advanced degrees (PhD/MD/JD/MPH/MBA) to volunteer on management consulting projects in order to gain practical training as well as educational and networking opportunities. The Solution Lab also provides programming for educational workshops and initiatives, with a focus on creative thinking and entrepreneurship.
Stefanie has professional background in payer side healthcare, allied health higher education, and management consulting. Stefanie earned an MBA from NYU Stern School of Business with specialization in Strategy and Finance, and a BA from The University of Chicago.
Subhshri Sahu
- Postdoctoral Research Associate, University of South Carolina
Subhshri Sahu is an experienced PHD with a demonstrated history of working in the research industry. Skilled in Life Sciences, Protein Purification, Cell Biology, Reverse Transcription Polymerase Chain Reaction (RT-PCR), and Tissue Culture. Strong research professional with a Master’s Degree focused in Animal biotechnology from University of Hyderabad.
Suzette DiMascio
- CEO, Women In Specialty Pharmacy
Recognized Internationally as a thought leader, industry expert, frequent media contributor, sought after key note speaker & educator of all things Specialty Pharmacy & Rare & Orphan Disease related; Suzette's strategic insight on marketplace trends help align & enlighten this continually pivoting industry.
Suzette founded CSI Specialty Group In 2002, serving as President/CEO for 17 years. Under her leadership, honors include being named as one of Consulting Magazine's Fastest Growing Firms, Goldman Sach’s Top Growing Businesses & Recipient for an unprecedented 4 years in a row, of the coveted CommonWealth Institute’s Top 50 Women Led Business, from 2014-2018.
As a reflection of her dedication to the industry & servant leadership philosophy, Suzette received APPA’s Hall of Fame Award, honoring the ways she champions to improve patient care & access, as well as always mentoring women to gain their rightful seat at the table through the Women in Specialty Pharmacy Organization she founded in 2013.
An advocate for life long learning, Suzette started the industry's first dedicated podcast, focused on uncovering ways to make the specialty pharmacy journey more successful for patients worldwide.
Appointed by Gov. Rick Scott of Florida to the Board of Employee Leasing, the rigorous selection process to be appointed to a State Board is a true testament to Ms. DiMascio’ s stellar ethical reputation in the industry she has served for over 25 years.
Suzette serves as a Board Member for NASP, AMCP & PQA, as well as the State of FL Innovation Caucus Board since 2008. Invited by the Governor’s office to spearhead FL's Talent Caucus, she was 1 of 50 women selected to participate in a Prestigious Executive Leadership Program at Tuck School of Business-Dartmouth & was 1 of only 14 women to receive the Dorothy Brothers Scholarship award by WBENC.
Suzette is a proud Member of AMCP, NASP, WBL, HBA, BIO, WBENC, ASHP & A Proud Mom of a Class of 2019 West Point Graduate.
Swagata Basu
- Scientific Collaborations Manager, DRVision Technologies
Dr. Swagata Basu is a science writer and market researcher by profession with a Ph.D. in neuroscience. She currently works as Scientific Collaborations Manager at DRVision Technologies where she manages federal SBIR grants and performs market research on emerging trends in scientific and pharmaceutical research. Swagata also contributes to the product management process and science communications. She previously worked as a Science Communications and Marketing Specialist at Inscopix, Inc. where she developed scientific content for training and outreach and for sales and marketing. Swagata has written blog posts, white papers, and technical manuals and has reviewed scholarly publications to ensure that they meet publication guidelines and objectives. Swagata's multidisciplinary background has allowed her to gain a comprehensive understanding of neurobiology and pharmaceutical research. She has developed and led insightful neuroscience research projects, while communicating the scientific results in peer-reviewed journals and conferences.
Ted Cho
- President, StartupHoyas MED
Ted Cho is an MD/MBA candidate at Georgetown University. He is the co-founder and president of StartupHoyas MED, a student organization dedicated to promoting healthcare entrepreneurship and innovation. He was awarded the Outstanding Entrepreneurial Leadership Award and the READ award at Georgetown University. Ted has also served as a Venture and Research Fellow at Rock Health, a venture fund focused on digital health, and an Operations Associate at Cigna, a global health service company offering health, pharmacy, and dental insurance. Ted received his BS in Biology from Duke University where he co-founded Kovo App, a social media platform for facilitating in-person conversations, and provided research and project management services to the Duke University Health System.
Temidayo Adebayo
- Managing Partner, BAYI Capital
Temidayo Adebayo is an experienced Investor with a demonstrated history investing in developing countries. He is skilled in Venture Capital & Private Equity Investment with an interest in social innovation and impact investing.
Tien Wong
- CEO, Opus8
Tien Wong is the CEO of Opus8 Inc., a private investment and strategic advisory firm based in Washington, DC. He also serves as the Chairman and CEO of Tech 2000 Inc, a company dedicated to technology training and mobile virtual education, and the Chairman of Lore Systems, a firm that provides enterprise network engineering and cloud computing systems to government and small/medium sized businesses. Tien has three decades of experience in business and entrepreneurship, starting as a co-founder and the CEO of Cyber Rep, one of the three largest private contact center companies in North America and eventually acquired by Xerox Corp. He was awarded the Ernst & Young Entrepreneur of the Year award for the DC area in 2001. Tien received his Bachelor’s in Government from Dartmouth College.
Tomasz Bakowski
Forecasting & Strategic Planning, Bristol Myers Squibb
Dr. Tomasz Bakowski is a PhD in Biomedical Engineering with a wide range of interests spanning science, healthcare, technology, and politics. He most recently applied his demonstrated, adaptable critical thinking, quantitative, and creative skills within team-based strategic consulting positions.
As a consultant Tomasz worked on a variety of projects ranging from new product commercialization, pricing/market access, and opportunity assessments across a wide range of therapeutic areas including oncology, cardiology, neurology, orphan disease, musculoskeletal diseases, and others. He has wide experience in secondary and primary research, with robust experience leading and designing both qualitative and quantitative studies.
For his PhD work, Tomasz was interested in understanding how DNA behaves during the many complex interactions and processes required for our cells to function; specifically, how DNA responds to different types of confinement. To that end, he designed, built, and characterized a custom fluorescence microscopy system, building it at a fifth of the cost of commercial systems boasting higher accuracy and reproducibility. From his research, Tomasz has extensive experience in nanotechnology, nanofabrication, polymer physics, optics, and varied microscopy/spectroscopy techniques.
Apart from research, his interests include reforming local politics, technology, video games, scuba diving (certified Rescue Scuba Diver), traveling, and eating large numbers of sweets!
Dr. Tomasz Bakowski is a PhD in Biomedical Engineering with a wide range of interests spanning science, healthcare, technology, and politics. He most recently applied his demonstrated, adaptable critical thinking, quantitative, and creative skills within team-based strategic consulting positions.
As a consultant Tomasz worked on a variety of projects ranging from new product commercialization, pricing/market access, and opportunity assessments across a wide range of therapeutic areas including oncology, cardiology, neurology, orphan disease, musculoskeletal diseases, and others. He has wide experience in secondary and primary research, with robust experience leading and designing both qualitative and quantitative studies.
For his PhD work, Tomasz was interested in understanding how DNA behaves during the many complex interactions and processes required for our cells to function; specifically, how DNA responds to different types of confinement. To that end, he designed, built, and characterized a custom fluorescence microscopy system, building it at a fifth of the cost of commercial systems boasting higher accuracy and reproducibility. From his research, Tomasz has extensive experience in nanotechnology, nanofabrication, polymer physics, optics, and varied microscopy/spectroscopy techniques.
Apart from research, his interests include reforming local politics, technology, video games, scuba diving (certified Rescue Scuba Diver), traveling, and eating large numbers of sweets!
Txomin Lalanne
- Co-founder and Président, EphyX Neuroscience
Txomin Lalanne is a passionate neuroscientist with 7+ years of experience in CNS (central nervous system) electrophysiology, which provides a critical insight into the physiology and physiopathology of neuronal cells. While our society ages, the prevalence of brain-related pathologies increases. Yet, pharma & biotech companies struggle to deal with the unique properties and functioning of the human brain that make CNS-related preclinical studies unreliable. Txomin strongly believes that improving existing electrophysiology recording approaches and methods can help overcome these challenges and benefit all of society by boosting and optimizing drug discovery and CNS-related preclinical studies.
Vania Cao
- APAC Sales Manager & Support Lead, Inscopix; Founder, Free the PhD
Dr. Vania Cao is an efficient cross-functional manager, specializing in strategic planning, targeted messaging and creative ways to build new initiatives from the ground up. She has experience in behavioral change management, product marketing, sales strategy, content marketing strategy and project management.
Vania excels in translating complex technical knowledge into engaging, compelling content spanning traditional to digital media. She thrives in fast-paced, team-oriented environments working on the bleeding edge of innovation.
In her free time, Vania is a start-up consultant, active advocate for women in STEM and Asian American issues, and Founder of Free the PhD, a career support platform with job hunt courses, coaching and an interactive, supportive community for scientists & other academically-trained STEM and academic professionals through the evolution of their identities and careers.
Wang-tsu Liu
- Chief Experience Officer, Happinss
A Serial entrepreneur at heart and avid Expeditioner with ample experience in remote photography and videography.
Launched his first company in 2006 organizing academic and trade missions from Mexico to China, in 2009 due to the swine influenza virus he was forced to shut down operations in Mexico and move to Canada. He started doing expeditions to remote locations and helped jumpstart a social media project called "The Expeditioners" which now has a following of more than 200K people on Facebook.
In 2014 when back to Mexico and joined the Ministry of Innovation Science and Technology in Jalisco as a coordinator of the tech startup ecosystem and a year later created my second Company, Xquest360 developing 360 video content productions, finally created a spinoff one year ago called Happinss VR which is an enterprise mindfulness VR solution to alleviate stress and anxiety in the workplace.
Yana Nigen
- Chief Marketing Officer, JobDiva
Yana Nigen, Chief Marketing Officer of JobDiva and Axelon, manages two global brands. Leveraging technology to optimize marketing and communications effectiveness in HR and Staffing, ensuring consistency of user experience, while focusing on building effective and consistent brands, Yana brings over 15 years of expertise in Marketing, HR, Talent Acquisition, event management, and sales enablement to JobDiva and Axelon. Prior to joining JobDiva in 2015, Yana led the Recruitment Marketing efforts at a global financial institution, BNY Mellon and was a mentee to executive board member Head of Global HR at BNY Mellon. She holds a Bachelor's Degree in Communications and a Master's of Science in Financial Securities. Yana Nigen has been an official member of the Forbes Communications Council since 2018 and was recently nominated for the Women in IT Editor's Choice Award in 2019.
Youness Ouahid Benkaddour
- CSO, Excellenting
Dr. Youness Ouahid Benkaddour is the founder of Excellenting: Innovation to Market, a technology scouting and open innovation consultancy firm. He has fifteen years of experience in science and health technology and has served as a scientific consultant for biotech seed capital investment as well as the Drug Discovery and Development Manager and Chief Laboratory Officer for Valoralia ImasD. Youness is an expert in cyanobacteria, receiving his PhD from the University of Autonoma de Madrid with focuses on environmental toxicology, analytical chemistry, and microbiology.
Yuqin Cai
- Senior Research Scientist, New York University
Dr. Yuqin Cai is a collaborative, highly motivated Senior Research Scientist proven in planning and execution of major Computational Biology projects. Her scientific expertise is in Chemical Carcinogenesis, DNA Damage, DNA Repair and Cancer. Yuqin uses an analytical approach to literature search, experimental design and data analysis to solve problems. She is proficient at framing and delivering complex oral and written reports in a timely manner.
Yuqin is a life-long learner with certifications in Medical Communications, Healthcare Branding Strategy, Design and Interpretation of Clinical Trials and Leadership program for Women in STEM. She is passionate about convergence of data science and life sciences for precision medicine.
Zobaer Ahmed
- Research Consultant
Zobaer Ahmed is a multidisciplinary, freelancer and international development specialist with 7 years of experience in the developmental sector project management, and implementation across 10 counties which include Southeast Asia (Bangladesh, India, Nepal, Malaysia), Central Europe (Belgium, France, Netherlands, Germany, Italy) and North America (USA) with 15+ renowned international organizations. Personal strengths include multitasking, working under tight schedules, collaborating with senior management, and maintaining a positive work ethic and attitude. Other areas of expertise include climate change adaptation, food security, agriculture, sustainability, entrepreneurship, technology, innovation, strategic planning, market research, field operation, relief, and logistic support.
